<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE sequence-cwu SYSTEM "us-sequence-listing-v1_3-2020-10-08.dtd" [ ]><sequence-cwu id="SEQLST-1"><publication-reference><document-id><country>US</country><doc-number>20230000998</doc-number><kind>A1</kind><date>20230105</date></document-id></publication-reference><number>1</number><sequence-list-new-rules><s100><s160>12</s160></s100><s200><s210>1</s210><s211>5</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 1Gly Gly Gly Gly Ser1               5</s400><s200><s210>2</s210><s211>110</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic polypeptide&#x201d;</s223></s220></s200><s400> 2Ala Arg Val Asp Gln Thr Pro Gln Thr Ile Thr Lys Glu Thr Gly Glu1               5                   10                  15Ser Leu Thr Ile Asn Cys Val Leu Arg Asp Ser Asn Cys Ala Leu Ser            20                  25                  30Ser Thr Tyr Trp Tyr Arg Lys Lys Ser Gly Ser Thr Asn Glu Glu Asn        35                  40                  45Ile Ser Lys Gly Gly Arg Tyr Val Glu Thr Val Asn Ser Gly Ser Lys    50                  55                  60Ser Phe Ser Leu Arg Ile Asn Asp Leu Thr Val Glu Asp Ser Gly Thr65                  70                  75                  80Tyr Arg Cys Asn Val Val Gln Tyr Pro Gln Tyr Pro Asn Tyr Phe Trp                85                  90                  95Cys Asp Val Tyr Gly Asp Gly Thr Ala Val Thr Val Asn Ala            100                 105                 110</s400><s200><s210>3</s210><s211>109</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic polypeptide&#x201d;</s223></s220></s200><s400> 3Ala Arg Val Asp Gln Thr Pro Gln Thr Ile Thr Lys Glu Thr Gly Glu1               5                   10                  15Ser Leu Thr Ile Asn Cys Val Leu Arg Asp Ser Asn Cys Ala Leu Ser            20                  25                  30Ser Thr Tyr Trp Tyr Arg Lys Lys Ser Gly Ser Thr Asn Glu Glu Asn        35                  40                  45Ile Ser Lys Gly Gly Arg Tyr Val Glu Thr Val Asn Ser Gly Ser Lys    50                  55                  60Ser Phe Ser Leu Arg Ile Asn Asp Leu Thr Val Glu Asp Ser Gly Thr65                  70                  75                  80Tyr Arg Cys Asn Val Val Gln Tyr Pro Ser Tyr Asn Asn Tyr Phe Trp                85                  90                  95Cys Asp Val Tyr Gly Asp Gly Thr Ala Val Thr Val Asn            100                 105</s400><s200><s210>4</s210><s211>111</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic polypeptide&#x201d;</s223></s220></s200><s400> 4Ala Arg Val Asp Gln Thr Pro Gln Thr Ile Thr Lys Glu Thr Gly Glu1               5                   10                  15Ser Leu Thr Ile Asn Cys Val Leu Arg Asp Ser Asn Cys Glu Leu Ser            20                  25                  30Ser Thr Tyr Trp Tyr Arg Lys Lys Ser Gly Ser Thr Asn Glu Glu Ser        35                  40                  45Ile Ser Lys Gly Gly Arg Tyr Val Glu Thr Val Asn Ser Gly Ser Lys    50                  55                  60Ser Phe Ser Leu Arg Ile Asn Asp Leu Val Val Glu Asp Ser Gly Thr65                  70                  75                  80Tyr Arg Cys Asn Val Gln Gln Phe Pro Ser Ser Ser Asn Gly Arg Tyr                85                  90                  95Trp Cys Asp Val Tyr Gly Gly Gly Thr Ala Val Thr Val Asn Ala            100                 105                 110</s400><s200><s210>5</s210><s211>114</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic polypeptide&#x201d;</s223></s220></s200><s400> 5Ala Arg Val Asp Gln Thr Pro Gln Thr Ile Thr Lys Glu Thr Gly Glu1               5                   10                  15Ser Leu Thr Ile Asn Cys Val Leu Arg Asp Ser Asn Cys Ala Leu Pro            20                  25                  30Ser Thr Tyr Trp Tyr Arg Lys Lys Ser Gly Ser Thr Asn Glu Glu Ser        35                  40                  45Ile Ser Lys Gly Gly Arg Tyr Val Glu Thr Val Asn Ser Gly Ser Lys    50                  55                  60Ser Phe Ser Leu Arg Ile Asn Asp Leu Thr Val Glu Asp Ser Gly Thr65                  70                  75                  80Tyr Arg Cys Lys Val Ile Ala Gln Leu Ser Ser Ile Leu Arg Gly Cys                85                  90                  95Asn Tyr Arg Lys His Asp Val Tyr Gly Asp Gly Thr Ala Val Thr Val            100                 105                 110Asn Ala</s400><s200><s210>6</s210><s211>107</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic polypeptide&#x201d;</s223></s220></s200><s400> 6Ala Arg Val Asp Gln Thr Pro Gln Thr Ile Thr Lys Glu Thr Gly Glu1               5                   10                  15Ser Leu Thr Ile Asn Cys Val Leu Arg Asp Ser Asn Cys Ala Leu Ser            20                  25                  30Ser Thr Tyr Trp Tyr Arg Lys Lys Ser Gly Ser Thr Asn Glu Glu Asn        35                  40                  45Ile Ser Lys Gly Gly Arg Tyr Val Glu Thr Val Asn Ser Gly Ser Lys    50                  55                  60Ser Phe Ser Leu Lys Ile Asn Asp Leu Thr Val Glu Asp Ser Gly Thr65                  70                  75                  80Tyr Arg Cys Asn Val Val Gly Thr Trp Cys Met Ser Trp Arg Asp Val                85                  90                  95Tyr Gly Gly Gly Thr Ala Val Thr Val Asn Ala            100                 105</s400><s200><s210>7</s210><s211>112</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic polypeptide&#x201d;</s223></s220></s200><s400> 7Ala Arg Val Asp Gln Thr Pro Gln Thr Ile Thr Lys Glu Glu Gly Glu1               5                   10                  15Ser Leu Thr Ile Asn Cys Val Leu Arg Val His Gly Arg Ala Leu Ala            20                  25                  30Ser Thr Ser Trp Tyr Arg Lys Lys Ser Gly Ser Thr Arg Glu Glu Thr        35                  40                  45Ile Ser Lys Gly Gly Arg Tyr Val Glu Thr Val Asn Ser Gly Ser Lys    50                  55                  60Ser Phe Ser Leu Arg Ile Asn Asp Leu Thr Val Glu Asp Ser Gly Thr65                  70                  75                  80Tyr Arg Cys Asn Val Tyr Gly Leu Ser Phe Gly Asp Ile Glu Gly Val                85                  90                  95Lys Lys Ile Asp Val Tyr Gly Asp Gly Thr Ala Val Thr Val Asn Ala            100                 105                 110</s400><s200><s210>8</s210><s211>15</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic peptide&#x201d;</s223></s220></s200><s400> 8Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser1               5                   10                  15</s400><s200><s210>9</s210><s211>214</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic polypeptide&#x201d;</s223></s220></s200><s400> 9Ala Ile Val Leu Ile Gln Ser Pro Ala Thr Leu Ser Val Thr Pro Gly1               5                   10                  15Asp Ser Val Ser Leu Ser Cys Arg Ala Ser Gln Thr Ile Ser Asn Asn            20                  25                  30Leu His Trp Tyr Gln Gln Lys Ser His Glu Ser Pro Arg Leu Leu Ile        35                  40                  45Lys Ser Ala Ser Leu Ala Ile Ser Gly Ile Pro Ser Arg Phe Ser Gly    50                  55                  60Ser Gly Ser Gly Thr Asp Phe Thr Leu Ser Ile Ser Ser Val Glu Thr65                  70                  75                  80Glu Asp Phe Gly Met Tyr Phe Cys Gln Gln Ser Asn Ser Trp Pro Asn                85                  90                  95Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala            100                 105                 110Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly        115                 120                 125Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala    130                 135                 140Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln145                 150                 155                 160Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser                165                 170                 175Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr            180                 185                 190Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser        195                 200                 205Phe Asn Arg Gly Glu Cys    210</s400><s200><s210>10</s210><s211>448</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic polypeptide&#x201d;</s223></s220></s200><s400> 10Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala1               5                   10                  15Ser Met Lys Ile Ser Cys Lys Thr Ser Gly Tyr Ser Phe Thr Ala Tyr            20                  25                  30Phe Met Asn Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile        35                  40                  45Gly Arg Ile Asn Pro Asn Asn Gly Asp Thr Phe Tyr Thr Gln Lys Phe    50                  55                  60Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Asn Thr Ala His65                  70                  75                  80Met Glu Leu Leu Ser Leu Thr Ser Glu Asp Ser Ala Ile Tyr Tyr Cys                85                  90                  95Gly Arg Arg Asp Tyr Phe Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr            100                 105                 110Ser Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro        115                 120                 125Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly    130                 135                 140Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn145                 150                 155                 160Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln                165                 170                 175Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser            180                 185                 190Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser        195                 200                 205Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr    210                 215                 220His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly Gly Pro Ser225                 230                 235                 240Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg                245                 250                 255Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro            260                 265                 270Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala        275                 280                 285Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val    290                 295                 300Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr305                 310                 315                 320Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr                325                 330                 335Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu            340                 345                 350Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys        355                 360                 365Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser    370                 375                 380Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp385                 390                 395                 400Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser                405                 410                 415Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala            420                 425                 430Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys        435                 440                 445</s400><s200><s210>11</s210><s211>573</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic polypeptide&#x201d;</s223></s220></s200><s400> 11Ala Arg Val Asp Gln Thr Pro Gln Thr Ile Thr Lys Glu Thr Gly Glu1               5                   10                  15Ser Leu Thr Ile Asn Cys Val Leu Arg Asp Ser Asn Cys Ala Leu Ser            20                  25                  30Ser Thr Tyr Trp Tyr Arg Lys Lys Ser Gly Ser Thr Asn Glu Glu Asn        35                  40                  45Ile Ser Lys Gly Gly Arg Tyr Val Glu Thr Val Asn Ser Gly Ser Lys    50                  55                  60Ser Phe Ser Leu Arg Ile Asn Asp Leu Thr Val Glu Asp Ser Gly Thr65                  70                  75                  80Tyr Arg Cys Asn Val Val Gln Tyr Pro Gln Tyr Pro Asn Tyr Phe Trp                85                  90                  95Cys Asp Val Tyr Gly Asp Gly Thr Ala Val Thr Val Asn Ala Gly Gly            100                 105                 110Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Val Gln        115                 120                 125Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Met Lys    130                 135                 140Ile Ser Cys Lys Thr Ser Gly Tyr Ser Phe Thr Ala Tyr Phe Met Asn145                 150                 155                 160Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile Gly Arg Ile                165                 170                 175Asn Pro Asn Asn Gly Asp Thr Phe Tyr Thr Gln Lys Phe Lys Gly Lys            180                 185                 190Ala Thr Leu Thr Val Asp Lys Ser Ser Asn Thr Ala His Met Glu Leu        195                 200                 205Leu Ser Leu Thr Ser Glu Asp Ser Ala Ile Tyr Tyr Cys Gly Arg Arg    210                 215                 220Asp Tyr Phe Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr225                 230                 235                 240Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro                245                 250                 255Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val            260                 265                 270Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala        275                 280                 285Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly    290                 295                 300Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly305                 310                 315                 320Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys                325                 330                 335Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys            340                 345                 350Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly Gly Pro Ser Val Phe Leu        355                 360                 365Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu    370                 375                 380Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys385                 390                 395                 400Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys                405                 410                 415Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu            420                 425                 430Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys        435                 440                 445Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys    450                 455                 460Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser465                 470                 475                 480Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys                485                 490                 495Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln            500                 505                 510Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly        515                 520                 525Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln    530                 535                 540Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn545                 550                 555                 560His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys                565                 570</s400><s200><s210>12</s210><s211>578</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s221>source</s221><s223>/note=&#x201c;Description of Artificial Sequence      Synthetic polypeptide&#x201d;</s223></s220></s200><s400> 12Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala1               5                   10                  15Ser Met Lys Ile Ser Cys Lys Thr Ser Gly Tyr Ser Phe Thr Ala Tyr            20                  25                  30Phe Met Asn Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile        35                  40                  45Gly Arg Ile Asn Pro Asn Asn Gly Asp Thr Phe Tyr Thr Gln Lys Phe    50                  55                  60Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Asn Thr Ala His65                  70                  75                  80Met Glu Leu Leu Ser Leu Thr Ser Glu Asp Ser Ala Ile Tyr Tyr Cys                85                  90                  95Gly Arg Arg Asp Tyr Phe Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr            100                 105                 110Ser Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro        115                 120                 125Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly    130                 135                 140Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn145                 150                 155                 160Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln                165                 170                 175Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser            180                 185                 190Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser        195                 200                 205Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Gly Gly Gly    210                 215                 220Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ala Arg Val Asp225                 230                 235                 240Gln Thr Pro Gln Thr Ile Thr Lys Glu Thr Gly Glu Ser Leu Thr Ile                245                 250                 255Asn Cys Val Leu Arg Asp Ser Asn Cys Ala Leu Ser Ser Thr Tyr Trp            260                 265                 270Tyr Arg Lys Lys Ser Gly Ser Thr Asn Glu Glu Asn Ile Ser Lys Gly        275                 280                 285Gly Arg Tyr Val Glu Thr Val Asn Ser Gly Ser Lys Ser Phe Ser Leu    290                 295                 300Arg Ile Asn Asp Leu Thr Val Glu Asp Ser Gly Thr Tyr Arg Cys Asn305                 310                 315                 320Val Val Gln Tyr Pro Gln Tyr Pro Asn Tyr Phe Trp Cys Asp Val Tyr                325                 330                 335Gly Asp Gly Thr Ala Val Thr Val Asn Ala Gly Gly Gly Gly Ser Asp            340                 345                 350Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly Gly        355                 360                 365Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile    370                 375                 380Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu385                 390                 395                 400Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His                405                 410                 415Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg            420                 425                 430Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys        435                 440                 445Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu    450                 455                 460Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr465                 470                 475                 480Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu                485                 490                 495Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp            500                 505                 510Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val        515                 520                 525Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp    530                 535                 540Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His545                 550                 555                 560Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro                565                 570                 575Gly Lys</s400></sequence-list-new-rules></sequence-cwu><?xml version="1.0" encoding="UTF-8"?><!DOCTYPE us-patent-application SYSTEM "us-patent-application-v46-2022-02-17.dtd" [ ]><us-patent-application lang="EN" dtd-version="v4.6 2022-02-17" file="US20230000999A1-20230105.XML" status="PRODUCTION" id="us-patent-application" country="US" date-produced="20221221" date-publ="20230105"><us-bibliographic-data-application lang="EN" country="US"><publication-reference><document-id><country>US</country><doc-number>20230000999</doc-number><kind>A1</kind><date>20230105</date></document-id></publication-reference><application-reference appl-type="utility"><document-id><country>US</country><doc-number>17788954</doc-number><date>20201224</date></document-id></application-reference><us-application-series-code>17</us-application-series-code><classifications-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>A</section><class>61</class><subclass>K</subclass><main-group>47</main-group><subgroup>64</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>C</section><class>07</class><subclass>K</subclass><main-group>7</main-group><subgroup>08</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>C</section><class>07</class><subclass>K</subclass><main-group>7</main-group><subgroup>06</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>C</section><class>07</class><subclass>K</subclass><main-group>7</main-group><subgroup>64</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>A</section><class>61</class><subclass>K</subclass><main-group>48</main-group><subgroup>00</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>A</section><class>61</class><subclass>K</subclass><main-group>47</main-group><subgroup>69</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>C</section><class>12</class><subclass>N</subclass><main-group>15</main-group><subgroup>113</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>C</section><class>12</class><subclass>N</subclass><main-group>15</main-group><subgroup>11</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>A</section><class>61</class><subclass>P</subclass><main-group>35</main-group><subgroup>00</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>A</section><class>61</class><subclass>K</subclass><main-group>8</main-group><subgroup>64</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>A</section><class>61</class><subclass>Q</subclass><main-group>19</main-group><subgroup>00</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>A</section><class>61</class><subclass>K</subclass><main-group>8</main-group><subgroup>60</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>A</section><class>61</class><subclass>K</subclass><main-group>47</main-group><subgroup>60</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr></classifications-ipcr><classifications-cpc><main-cpc><classification-cpc><cpc-version-indicator><date>20170801</date></cpc-version-indicator><section>A</section><class>61</class><subclass>K</subclass><main-group>47</main-group><subgroup>6455</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc></main-cpc><further-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>07</class><subclass>K</subclass><main-group>7</main-group><subgroup>08</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>07</class><subclass>K</subclass><main-group>7</main-group><subgroup>06</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>07</class><subclass>K</subclass><main-group>7</main-group><subgroup>64</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>A</section><class>61</class><subclass>K</subclass><main-group>48</main-group><subgroup>0033</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20170801</date></cpc-version-indicator><section>A</section><class>61</class><subclass>K</subclass><main-group>47</main-group><subgroup>6923</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20170801</date></cpc-version-indicator><section>A</section><class>61</class><subclass>K</subclass><main-group>47</main-group><subgroup>6929</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>12</class><subclass>N</subclass><main-group>15</main-group><subgroup>113</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>12</class><subclass>N</subclass><main-group>15</main-group><subgroup>11</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20180101</date></cpc-version-indicator><section>A</section><class>61</class><subclass>P</subclass><main-group>35</main-group><subgroup>00</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>A</section><class>61</class><subclass>K</subclass><main-group>8</main-group><subgroup>64</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>A</section><class>61</class><subclass>Q</subclass><main-group>19</main-group><subgroup>00</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>A</section><class>61</class><subclass>K</subclass><main-group>8</main-group><subgroup>606</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20170801</date></cpc-version-indicator><section>A</section><class>61</class><subclass>K</subclass><main-group>47</main-group><subgroup>60</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>12</class><subclass>N</subclass><main-group>2310</main-group><subgroup>3513</subgroup><symbol-position>L</symbol-position><classification-value>A</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>12</class><subclass>N</subclass><main-group>2310</main-group><subgroup>14</subgroup><symbol-position>L</symbol-position><classification-value>A</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20170501</date></cpc-version-indicator><section>C</section><class>12</class><subclass>N</subclass><main-group>2310</main-group><subgroup>20</subgroup><symbol-position>L</symbol-position><classification-value>A</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>12</class><subclass>N</subclass><main-group>2320</main-group><subgroup>32</subgroup><symbol-position>L</symbol-position><classification-value>A</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc></further-cpc></classifications-cpc><invention-title id="d2e43">COMPOSITIONS AND METHODS FOR NUCLEIC ACID DELIVERY</invention-title><us-related-documents><us-provisional-application><document-id><country>US</country><doc-number>63013843</doc-number><date>20200422</date></document-id></us-provisional-application><us-provisional-application><document-id><country>US</country><doc-number>62953365</doc-number><date>20191224</date></document-id></us-provisional-application></us-related-documents><us-parties><us-applicants><us-applicant sequence="00" app-type="applicant-inventor" designation="us-only" applicant-authority-category="inventor"><addressbook><last-name>PARANG</last-name><first-name>Keykavous</first-name><address><city>Irvine</city><state>CA</state><country>US</country></address></addressbook><residence><country>US</country></residence></us-applicant><us-applicant sequence="01" app-type="applicant-inventor" designation="us-only" applicant-authority-category="inventor"><addressbook><last-name>MONTAZERI ALIABADI</last-name><first-name>Hamidreza</first-name><address><city>Santa Margarita</city><state>CA</state><country>US</country></address></addressbook><residence><country>US</country></residence></us-applicant><us-applicant sequence="02" app-type="applicant-inventor" designation="us-only" applicant-authority-category="inventor"><addressbook><last-name>MANDAL</last-name><first-name>Dindyal</first-name><address><city>Lake Forest</city><state>CA</state><country>US</country></address></addressbook><residence><country>US</country></residence></us-applicant><us-applicant sequence="03" app-type="applicant-inventor" designation="us-only" applicant-authority-category="inventor"><addressbook><last-name>MOHAMMED</last-name><first-name>Eman</first-name><address><city>Menoufia</city><country>EG</country></address></addressbook><residence><country>EG</country></residence></us-applicant><us-applicant sequence="04" app-type="applicant-inventor" designation="us-only" applicant-authority-category="inventor"><addressbook><last-name>MOZAFFARI</last-name><first-name>Saghar</first-name><address><city>Irvine</city><state>CA</state><country>US</country></address></addressbook><residence><country>US</country></residence></us-applicant><us-applicant sequence="05" app-type="applicant-inventor" designation="us-only" applicant-authority-category="inventor"><addressbook><last-name>LOHAN</last-name><first-name>Sandeep</first-name><address><city>Lake Forest</city><state>CA</state><country>US</country></address></addressbook><residence><country>US</country></residence></us-applicant><us-applicant sequence="06" app-type="applicant-inventor" designation="us-only" applicant-authority-category="inventor"><addressbook><last-name>TIWARI</last-name><first-name>Rakesh</first-name><address><city>Irvine</city><state>CA</state><country>US</country></address></addressbook><residence><country>US</country></residence></us-applicant><us-applicant sequence="07" app-type="applicant-inventor" designation="us-only" applicant-authority-category="inventor"><addressbook><last-name>HALL</last-name><first-name>Ryley</first-name><address><city>Tacoma</city><state>WA</state><country>US</country></address></addressbook><residence><country>US</country></residence></us-applicant><us-applicant sequence="08" app-type="applicant" designation="us-only" applicant-authority-category="assignee"><addressbook><orgname>AJK BIOPHARMACEUTICAL, LLC</orgname><address><city>Irvine</city><state>CA</state><country>US</country></address></addressbook><residence><country>US</country></residence></us-applicant></us-applicants><inventors><inventor sequence="00" designation="us-only"><addressbook><last-name>PARANG</last-name><first-name>Keykavous</first-name><address><city>Irvine</city><state>CA</state><country>US</country></address></addressbook></inventor><inventor sequence="01" designation="us-only"><addressbook><last-name>MONTAZERI ALIABADI</last-name><first-name>Hamidreza</first-name><address><city>Santa Margarita</city><state>CA</state><country>US</country></address></addressbook></inventor><inventor sequence="02" designation="us-only"><addressbook><last-name>MANDAL</last-name><first-name>Dindyal</first-name><address><city>Lake Forest</city><state>CA</state><country>US</country></address></addressbook></inventor><inventor sequence="03" designation="us-only"><addressbook><last-name>MOHAMMED</last-name><first-name>Eman</first-name><address><city>Menoufia</city><country>EG</country></address></addressbook></inventor><inventor sequence="04" designation="us-only"><addressbook><last-name>MOZAFFARI</last-name><first-name>Saghar</first-name><address><city>Irvine</city><state>CA</state><country>US</country></address></addressbook></inventor><inventor sequence="05" designation="us-only"><addressbook><last-name>LOHAN</last-name><first-name>Sandeep</first-name><address><city>Lake Forest</city><state>CA</state><country>US</country></address></addressbook></inventor><inventor sequence="06" designation="us-only"><addressbook><last-name>TIWARI</last-name><first-name>Rakesh</first-name><address><city>Irvine</city><state>CA</state><country>US</country></address></addressbook></inventor><inventor sequence="07" designation="us-only"><addressbook><last-name>HALL</last-name><first-name>Ryley</first-name><address><city>Tacoma</city><state>WA</state><country>US</country></address></addressbook></inventor></inventors></us-parties><pct-or-regional-filing-data><document-id><country>WO</country><doc-number>PCT/US2020/067036</doc-number><date>20201224</date></document-id><us-371c12-date><date>20220624</date></us-371c12-date></pct-or-regional-filing-data></us-bibliographic-data-application><abstract id="abstract"><p id="p-0001" num="0000">Peptide-based systems containing hydrophobic amino acids (e.g., tryptophan), charged amino acids (e.g., arginine), and/or sulfur-containing amino acids (e.g., cysteine), which can be used either alone or in combination with nanoparticles (e.g., gold or silver nanoparticles) for siRNA delivery into living cells are disclosed.</p></abstract><drawings id="DRAWINGS"><figure id="Fig-EMI-D00000" num="00000"><img id="EMI-D00000" he="39.29mm" wi="134.11mm" file="US20230000999A1-20230105-D00000.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00001" num="00001"><img id="EMI-D00001" he="148.84mm" wi="131.40mm" file="US20230000999A1-20230105-D00001.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00002" num="00002"><img id="EMI-D00002" he="164.08mm" wi="148.34mm" file="US20230000999A1-20230105-D00002.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00003" num="00003"><img id="EMI-D00003" he="223.44mm" wi="140.63mm" file="US20230000999A1-20230105-D00003.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00004" num="00004"><img id="EMI-D00004" he="139.02mm" wi="140.63mm" file="US20230000999A1-20230105-D00004.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00005" num="00005"><img id="EMI-D00005" he="147.07mm" wi="140.63mm" file="US20230000999A1-20230105-D00005.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00006" num="00006"><img id="EMI-D00006" he="158.24mm" wi="140.63mm" file="US20230000999A1-20230105-D00006.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00007" num="00007"><img id="EMI-D00007" he="146.73mm" wi="140.12mm" file="US20230000999A1-20230105-D00007.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00008" num="00008"><img id="EMI-D00008" he="161.54mm" wi="140.63mm" file="US20230000999A1-20230105-D00008.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00009" num="00009"><img id="EMI-D00009" he="162.64mm" wi="140.63mm" file="US20230000999A1-20230105-D00009.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00010" num="00010"><img id="EMI-D00010" he="171.11mm" wi="140.63mm" file="US20230000999A1-20230105-D00010.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00011" num="00011"><img id="EMI-D00011" he="179.49mm" wi="140.63mm" file="US20230000999A1-20230105-D00011.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00012" num="00012"><img id="EMI-D00012" he="187.11mm" wi="140.63mm" file="US20230000999A1-20230105-D00012.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00013" num="00013"><img id="EMI-D00013" he="177.55mm" wi="140.63mm" file="US20230000999A1-20230105-D00013.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00014" num="00014"><img id="EMI-D00014" he="228.18mm" wi="157.14mm" file="US20230000999A1-20230105-D00014.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00015" num="00015"><img id="EMI-D00015" he="243.84mm" wi="160.53mm" file="US20230000999A1-20230105-D00015.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00016" num="00016"><img id="EMI-D00016" he="151.64mm" wi="139.11mm" file="US20230000999A1-20230105-D00016.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00017" num="00017"><img id="EMI-D00017" he="145.71mm" wi="127.34mm" file="US20230000999A1-20230105-D00017.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00018" num="00018"><img id="EMI-D00018" he="157.48mm" wi="134.45mm" file="US20230000999A1-20230105-D00018.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00019" num="00019"><img id="EMI-D00019" he="157.48mm" wi="130.81mm" file="US20230000999A1-20230105-D00019.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00020" num="00020"><img id="EMI-D00020" he="157.48mm" wi="135.13mm" file="US20230000999A1-20230105-D00020.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00021" num="00021"><img id="EMI-D00021" he="161.63mm" wi="142.92mm" file="US20230000999A1-20230105-D00021.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00022" num="00022"><img id="EMI-D00022" he="173.74mm" wi="150.11mm" file="US20230000999A1-20230105-D00022.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00023" num="00023"><img id="EMI-D00023" he="181.44mm" wi="116.84mm" file="US20230000999A1-20230105-D00023.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00024" num="00024"><img id="EMI-D00024" he="212.60mm" wi="160.70mm" orientation="landscape" file="US20230000999A1-20230105-D00024.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00025" num="00025"><img id="EMI-D00025" he="141.05mm" wi="155.11mm" orientation="landscape" file="US20230000999A1-20230105-D00025.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00026" num="00026"><img id="EMI-D00026" he="152.32mm" wi="158.16mm" orientation="landscape" file="US20230000999A1-20230105-D00026.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00027" num="00027"><img id="EMI-D00027" he="238.76mm" wi="124.63mm" file="US20230000999A1-20230105-D00027.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00028" num="00028"><img id="EMI-D00028" he="244.69mm" wi="128.10mm" file="US20230000999A1-20230105-D00028.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00029" num="00029"><img id="EMI-D00029" he="191.35mm" wi="96.69mm" orientation="landscape" file="US20230000999A1-20230105-D00029.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00030" num="00030"><img id="EMI-D00030" he="215.56mm" wi="97.96mm" orientation="landscape" file="US20230000999A1-20230105-D00030.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00031" num="00031"><img id="EMI-D00031" he="241.81mm" wi="91.61mm" orientation="landscape" file="US20230000999A1-20230105-D00031.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00032" num="00032"><img id="EMI-D00032" he="203.54mm" wi="129.20mm" file="US20230000999A1-20230105-D00032.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00033" num="00033"><img id="EMI-D00033" he="190.75mm" wi="117.60mm" file="US20230000999A1-20230105-D00033.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00034" num="00034"><img id="EMI-D00034" he="161.54mm" wi="117.60mm" file="US20230000999A1-20230105-D00034.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00035" num="00035"><img id="EMI-D00035" he="134.03mm" wi="133.77mm" orientation="landscape" file="US20230000999A1-20230105-D00035.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00036" num="00036"><img id="EMI-D00036" he="140.72mm" wi="139.02mm" orientation="landscape" file="US20230000999A1-20230105-D00036.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00037" num="00037"><img id="EMI-D00037" he="171.20mm" wi="144.44mm" orientation="landscape" file="US20230000999A1-20230105-D00037.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00038" num="00038"><img id="EMI-D00038" he="219.79mm" wi="129.37mm" orientation="landscape" file="US20230000999A1-20230105-D00038.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00039" num="00039"><img id="EMI-D00039" he="237.49mm" wi="123.02mm" orientation="landscape" file="US20230000999A1-20230105-D00039.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00040" num="00040"><img id="EMI-D00040" he="241.22mm" wi="156.29mm" orientation="landscape" file="US20230000999A1-20230105-D00040.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00041" num="00041"><img id="EMI-D00041" he="215.65mm" wi="146.47mm" orientation="landscape" file="US20230000999A1-20230105-D00041.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00042" num="00042"><img id="EMI-D00042" he="214.97mm" wi="155.02mm" orientation="landscape" file="US20230000999A1-20230105-D00042.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00043" num="00043"><img id="EMI-D00043" he="219.29mm" wi="143.26mm" orientation="landscape" file="US20230000999A1-20230105-D00043.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00044" num="00044"><img id="EMI-D00044" he="241.89mm" wi="160.87mm" orientation="landscape" file="US20230000999A1-20230105-D00044.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00045" num="00045"><img id="EMI-D00045" he="216.32mm" wi="160.19mm" orientation="landscape" file="US20230000999A1-20230105-D00045.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00046" num="00046"><img id="EMI-D00046" he="213.87mm" wi="152.99mm" orientation="landscape" file="US20230000999A1-20230105-D00046.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00047" num="00047"><img id="EMI-D00047" he="240.54mm" wi="147.32mm" file="US20230000999A1-20230105-D00047.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00048" num="00048"><img id="EMI-D00048" he="225.55mm" wi="158.58mm" file="US20230000999A1-20230105-D00048.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00049" num="00049"><img id="EMI-D00049" he="244.43mm" wi="155.79mm" file="US20230000999A1-20230105-D00049.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00050" num="00050"><img id="EMI-D00050" he="244.94mm" wi="162.05mm" file="US20230000999A1-20230105-D00050.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00051" num="00051"><img id="EMI-D00051" he="220.13mm" wi="153.25mm" file="US20230000999A1-20230105-D00051.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00052" num="00052"><img id="EMI-D00052" he="199.81mm" wi="150.71mm" orientation="landscape" file="US20230000999A1-20230105-D00052.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00053" num="00053"><img id="EMI-D00053" he="194.06mm" wi="157.14mm" orientation="landscape" file="US20230000999A1-20230105-D00053.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00054" num="00054"><img id="EMI-D00054" he="194.31mm" wi="154.18mm" orientation="landscape" file="US20230000999A1-20230105-D00054.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00055" num="00055"><img id="EMI-D00055" he="194.06mm" wi="154.69mm" orientation="landscape" file="US20230000999A1-20230105-D00055.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00056" num="00056"><img id="EMI-D00056" he="194.06mm" wi="153.75mm" orientation="landscape" file="US20230000999A1-20230105-D00056.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00057" num="00057"><img id="EMI-D00057" he="194.06mm" wi="146.30mm" orientation="landscape" file="US20230000999A1-20230105-D00057.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00058" num="00058"><img id="EMI-D00058" he="194.06mm" wi="146.30mm" orientation="landscape" file="US20230000999A1-20230105-D00058.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00059" num="00059"><img id="EMI-D00059" he="211.58mm" wi="150.88mm" file="US20230000999A1-20230105-D00059.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00060" num="00060"><img id="EMI-D00060" he="221.15mm" wi="152.32mm" file="US20230000999A1-20230105-D00060.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00061" num="00061"><img id="EMI-D00061" he="185.93mm" wi="95.76mm" orientation="landscape" file="US20230000999A1-20230105-D00061.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00062" num="00062"><img id="EMI-D00062" he="221.83mm" wi="145.12mm" file="US20230000999A1-20230105-D00062.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00063" num="00063"><img id="EMI-D00063" he="228.26mm" wi="145.12mm" file="US20230000999A1-20230105-D00063.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00064" num="00064"><img id="EMI-D00064" he="234.27mm" wi="144.19mm" file="US20230000999A1-20230105-D00064.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00065" num="00065"><img id="EMI-D00065" he="228.01mm" wi="155.28mm" file="US20230000999A1-20230105-D00065.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00066" num="00066"><img id="EMI-D00066" he="236.39mm" wi="143.09mm" file="US20230000999A1-20230105-D00066.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00067" num="00067"><img id="EMI-D00067" he="236.39mm" wi="143.09mm" file="US20230000999A1-20230105-D00067.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00068" num="00068"><img id="EMI-D00068" he="238.51mm" wi="145.03mm" file="US20230000999A1-20230105-D00068.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00069" num="00069"><img id="EMI-D00069" he="222.59mm" wi="133.35mm" file="US20230000999A1-20230105-D00069.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00070" num="00070"><img id="EMI-D00070" he="231.82mm" wi="133.86mm" file="US20230000999A1-20230105-D00070.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00071" num="00071"><img id="EMI-D00071" he="217.17mm" wi="160.10mm" orientation="landscape" file="US20230000999A1-20230105-D00071.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00072" num="00072"><img id="EMI-D00072" he="151.55mm" wi="160.95mm" orientation="landscape" file="US20230000999A1-20230105-D00072.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00073" num="00073"><img id="EMI-D00073" he="226.74mm" wi="150.62mm" file="US20230000999A1-20230105-D00073.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00074" num="00074"><img id="EMI-D00074" he="226.40mm" wi="150.62mm" file="US20230000999A1-20230105-D00074.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00075" num="00075"><img id="EMI-D00075" he="237.07mm" wi="129.37mm" orientation="landscape" file="US20230000999A1-20230105-D00075.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00076" num="00076"><img id="EMI-D00076" he="238.08mm" wi="132.84mm" orientation="landscape" file="US20230000999A1-20230105-D00076.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00077" num="00077"><img id="EMI-D00077" he="202.44mm" wi="89.07mm" orientation="landscape" file="US20230000999A1-20230105-D00077.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00078" num="00078"><img id="EMI-D00078" he="210.74mm" wi="152.40mm" orientation="landscape" file="US20230000999A1-20230105-D00078.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00079" num="00079"><img id="EMI-D00079" he="213.11mm" wi="93.81mm" orientation="landscape" file="US20230000999A1-20230105-D00079.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00080" num="00080"><img id="EMI-D00080" he="199.14mm" wi="145.71mm" file="US20230000999A1-20230105-D00080.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00081" num="00081"><img id="EMI-D00081" he="230.97mm" wi="146.39mm" file="US20230000999A1-20230105-D00081.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00082" num="00082"><img id="EMI-D00082" he="216.92mm" wi="146.56mm" file="US20230000999A1-20230105-D00082.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00083" num="00083"><img id="EMI-D00083" he="212.60mm" wi="144.36mm" file="US20230000999A1-20230105-D00083.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00084" num="00084"><img id="EMI-D00084" he="200.58mm" wi="117.35mm" orientation="landscape" file="US20230000999A1-20230105-D00084.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00085" num="00085"><img id="EMI-D00085" he="155.70mm" wi="161.46mm" file="US20230000999A1-20230105-D00085.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00086" num="00086"><img id="EMI-D00086" he="235.80mm" wi="66.21mm" orientation="landscape" file="US20230000999A1-20230105-D00086.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure></drawings><description id="description"><?cross-reference-to-related-applications description="Cross Reference To Related Applications" end="lead"?><heading id="h-0001" level="1">CROSS REFERENCE TO RELATED APPLICATIONS</heading><p id="p-0002" num="0001">This application claims the benefit of priority to U.S. Provisional Application No. 62/953,365, filed Dec. 24. 2019, and No. 63/013,843, filed Apr. 22, 2020, the disclosures of which are incorporated by reference herein in their entireties.</p><?cross-reference-to-related-applications description="Cross Reference To Related Applications" end="tail"?><?summary-of-invention description="Summary of Invention" end="lead"?><heading id="h-0002" level="1">FIELD</heading><p id="p-0003" num="0002">The disclosed subject matter relates to delivery of nucleic acids (DNA, plasmids, oligos, small interfering RNAs [siRNA], small hairpin RNA [shRNA], microRNAs [miRNA], Clustered Regularly Interspaced Short Palindromic Repeats [CRISPR]) using a peptide-based delivery system to living cells.</p><heading id="h-0003" level="1">BACKGROUND</heading><p id="p-0004" num="0003">Nucleic acid delivery is an approach to suppress (or enhance) the expression of a protein temporarily or permanently. The suppression of protein expression (also known as silencing) is performed by delivering double-stranded siRNAs, shRNA, miRNA, or CRISPR/Cas9. RNA interference (RNAi) is an approach to suppress (or stop) the expression of a protein temporarily or permanently. The double stranded siRNA contains a passenger and a guide strand. The guide strand is incorporated into the RNA-induced silencing complex (RISC), while the passenger strand is degraded. The guide strand acts as a complementary sequence to the messenger RNA, and therefore, binds to the targeted mRNA, which triggers the Argonaute 2 (an essential catalytic protein in RISC) to cleavage the mRNA to small pieces, which will be degraded rapidly by RNases. This process is known as the post-transcriptional gene silencing (Akinc et al., Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. <i>Mol Ther, </i>2010, 18(7):1357-64), This complex intervenes in the degradation process of the siRNA sense strand and utilizes the preserved anti-sense strand to identify the complement sequences of mRNA.</p><p id="p-0005" num="0004">Clinical evaluation of nucleic acids has been challenging due to their limited cellular uptake (because of large size and negatively charged phosphate groups in their structure), off-target effects, and rapid enzymatic degradation in vivo. Even though double stranded nucleotides are generally more stable, siRNA is still extremely susceptible to enzymatic degradation in biological settings (Layzer et al., In vivo activity of nuclease-resistant siRNAs. <i>RNA, </i>2004, 10(5):765-71). Also, due to its small size, siRNA is readily eliminated from the body through glomerular filtration. In many animal studies, renal clearance of siRNA correlated to higher uptake activities fan de Water et al., Intravenously administered short interfering RNA accumulates in the kidney and selectively suppresses gene function in renal proximal tubules, <i>Drug Metab Dispos, </i>2006, 34(8): 1:393 -7). Clearance occurs in the kidney where the phagocytes aggregate the siRNA by using the serum proteins. The nuclease degradation of siRNA can occur by the reticuloendothelial system (RES). Finally, the negatively charged and hydrophilic small RNA structures have minimal interaction with the cell membrane (which is also negatively charged), and therefore, the cellular internalization is negligible.</p><p id="p-0006" num="0005">Several delivery systems have been evaluated to improve the efficiency of siRNA, which include polymers, lipids, liposomes, and carbon nanotubes (Liu et al., SiRNA delivery systems based on neutral cross-linked dendrimers. <i>Bioconjug Chem, </i>2012, 23(2):174-83; Chabot et al., Targeted electro-delivery of oligonucleotides for RNA interference: siRNA and antimiR. <i>Adv Drug Deliv Rev, </i>2015, 81:161-8; de Fougerolles et al., Interfering with disease: a progress report on siRNA-based therapeutics. <i>NatRev Drug Discov, </i>2007, 6(6):443-53; Golzio et al., In vivo gene silencing in solid tumors by targeted electrically mediated siRNA delivery. <i>Gene Ther, </i>2007, 14(9):752-9; Oh et al., siRNA delivery systems for cancer treatment. <i>Adv Drug Deliv Rev, </i>2009, 61(10):850-62), However, the majority of the delivery systems exhibited significant cytotoxicity and/or demonstrated limited in vivo and clinical potential. For example, poly(ethyleneimine) (PEI) is a commonly used polymeric carrier for siRNA delivery. The use of PEI facilitates the endosomal release of siRNA in the cellular cytoplasm. However, PEI induces toxicity contributes to low transfection efficiency (Guo et al., Engineering RNA for targeted siRNA delivery and medical application. <i>Adv Drug Deliv Rev, </i>2010, 62(6):650-66).</p><p id="p-0007" num="0006">Because of the great therapeutic potential of nucleic acids, developing efficient delivery systems is highly demanded in clinical investigations. FDA recently approved Onpattro&#x2122; (siRNA/lipid complex) for the treatment of hATTR amyloidosis. The delivery systems should be biodegradable to minimize the toxicity in the cytoplasm. Cell-penetrating peptides (CPPs) have drawn significant attention in the drug delivery field. CPPS take advantage of their unpatrolled properties like biocompatibility and cell penetration ability to pass the plasma membrane or through endocytic pathways. The intrinsic property of CPPs to deliver therapeutic molecules (nucleic acids, drugs, imaging agents) to cells and tissues in a nontoxic manner has indicated that they may be beneficial for enhancing the cellular delivery of drugs and diagnostic agents with limited cellular uptake. The modification of CPPs is required to act as delivery vectors for nucleic acid delivery to enhance interaction with the nucleic acid and to minimize the degradation and mediate the efficient cellular uptake. Often, the modification of CPPs can occur by attaching hydrophilic and hydrophobic lipid tails via linker residues. Attachment of lipids to the CPPs has been shown to facilitate membrane interactions and improve cellular uptake (Hafez et al., On the mechanism whereby cationic lipids promote intracellular delivery of poly nucleic acids. <i>Gene Ther, </i>2001, 8(15):1188-96).</p><p id="p-0008" num="0007">Cyclic peptides containing alternate tryptophan and arginine residues [WR]<sub>5 </sub>(SEQ ID NO.: 1) and [WR]<sub>4</sub>(SEQ ID NO.: 2) (<figref idref="DRAWINGS">FIG. <b>1</b></figref>) and the corresponding peptide-capped gold nanoparticles were found to act as efficient molecular transporters of siRNA in human cervix adenocarcinoma (HeLa) cells (Nasrolahi Shirazi et al., Cyclic peptide-capped gold nanoparticles for enhanced siRNA delivery. <i>Molecules </i>2014, 19:13319-13331). Flow cytometry studies showed that [SVR]<sub>5 </sub>(SEQ ID NO.: 1) and [WR]<sub>5</sub>-capped gold nanoparticles improved the intracellular uptake of siRNA versus siRNA alone. It was also found that both delivery platforms were less toxic when compared with lipofectamine. Fluorescence microscopy data confirmed the localization of fluorescence-labeled siRNA in the presence of [WR]<sub>5 </sub>(SEQ ID NO.: 1) and [WR]<sub>5</sub>-capped gold nanoparticles. Thus, the positively charged residues on the peptide could have electrostatic interactions with negatively charged phosphate residues in the phospholipid bilayer and siRNA. Furthermore, the hydrophobic tryptophan groups could interact with hydrophobic residues in the lipid membrane. The efficacy of fatty acid-conjugated linear and cyclic arginine/lysine peptides in delivering siRNA to breast cancer cells and the efficacy of protein silencing via this approach was also shown (Do et al., Difatty Acyl-conjugated linear and cyclic peptides for siRNA Delivery. <i>ACS Omega </i>2017, 2:6939-6957). A variety of linear and cyclic peptides were synthesized with various fatty acyl conjugations with different lengths (from C2 to C18) and degree of saturation (<figref idref="DRAWINGS">FIGS. <b>2</b> and <b>3</b></figref>). Most recently, the potential of [WR]<sub>5</sub>(SEQ ID NO.: 1) for siRNA delivery was further confirmed (Mozaffari et al., Amphiphilic peptides for efficient siRNA delivery, <i>Polymers </i>2019, 11(4):703).</p><p id="p-0009" num="0008">The delivery of siRNA complexes has been improved by targeting surface biomarker exclusively overexpressed on the disease's cells. One such example is targeting the <b>60</b> v&#x3b2;3 integrin receptor in the angiogenic blood cells and tumor using linear or cyclic RGD peptide to improve the delivery of siRNA to the cancerous cells (Fu et al., RGD peptide-based non-viral gene delivery vectors targeting integrin &#x3b1;v &#x3b2;3 for cancer therapy. <i>J Drug Target </i>2019, 27:1-11).</p><p id="p-0010" num="0009">Thus, there is still a need for compositions and methods that provide efficient and non-toxic delivery of siRNAs to living cells. The compositions and methods disclosed herein addresses these and other needs.</p><heading id="h-0004" level="1">SUMMARY</heading><p id="p-0011" num="0010">Disclosed herein is a peptide-based systems containing hydrophobic amino acids (e.g., tryptophan), charged amino acids (e.g., arginine), and/or sulfur-containing amino acids (e.g., cysteine), which can be used either alone or in combination with nanoparticles (e.g., gold or silver nanoparticles) for siRNA delivery into living cells. Some of the peptides contain a disulfide bridge for cyclization and two chains of hydrophobic tryptophan residues. The amphiphilic cyclic and linear peptides and the corresponding peptide-capped gold nanoparticles were compared for siRNA delivery (Nasrolahi Shirazi et al., 2014). The rationale of this design is based on the data that a cyclic peptide [WR]<sub>5 </sub>(SEQ ID NO.: 1) containing alternating tryptophan (W) and arginine (R) residues (e.g., WRWR ((SEQ ID NO.: 3)) significantly enhanced the cellular uptake of negatively charged phosphopeptides and siRNA (Nasrolahi Shirazi et al., 2014).</p><p id="p-0012" num="0011">Peptide carriers containing tryptophan, arginine, and/or cysteine for binding with siRNA, protection against enzymatic degradation, cellular internalization, and silencing are disclosed. The peptides and their corresponding gold nanoparticles were used in different ratios with siRNA for comparative studies in cancer cells. Furthermore, the effect of hydrophobic modification of the formulation of each peptide/siRNA complex was also evaluated. The size and surface electrical charge were evaluated for the complexes formed via ionic interaction between the peptides and siRNA to confirm complex formation and neutralization of siRNA negative charge and to evaluate the physical characteristics of the complex. The binding affinity of the peptides to siRNA were analyzed to determine the effect of peptide and the size of the conjugate on the inter-ionic interaction. The ability of the peptides in protecting siRNA against early enzymatic degradation was investigated by exposing the complexes to fetal bovine serum, and the toxicity of the peptides was explored in different human cancer cell lines. Finally, the efficiency of the peptides in internalizing siRNA into different human cancer cells was studied, which was confirmed by silencing efficiency for specific proteins.</p><p id="p-0013" num="0012">Although embodiments that incorporate siRNAs are described at length, peptide and/or peptide-capped nanoparticles are useful for the delivery of other species of nucleic acid (e.g., ssDNA, dsDNA, DNA:RNA hybrids, etc.) as well as other negatively charged polymer species. As such, compositions and methods disclosed herein can be utilized in gene silencing, transient expression, and transient or permanent genetic modification in living cells,</p><p id="p-0014" num="0013">Delivery of short interfering RNAs (siRNAs) remains a major challenge in the development of RNA interference therapeutics. siRNA is a class of double-stranded RNA molecules that are about 20-25 base pairs. An optimal siRNA delivery system for in vivo use must facilitate cellular uptake and enhance its activity. Second, it must direct the siRNA toward the target tissue effectively.</p><p id="p-0015" num="0014">Compositions disclosed herein can include linear, cyclic, and/or hybrid linear/cyclic peptides containing natural or non-natural positively-charged amino acids, hydrophobic residues, and/or cysteine residues for use as siRNA delivery systems. Disclosed herein are four classes of peptides, which can include the addition of cysteine residues that can form disulfide bonds, modifications, such as the substitution of L-amino acid with D-amino acids to avoid proteolytic enzymes, the substitution of positively charge arginine or hydrophobic residues with non-natural amino acids, have significantly higher stability, loading efficiency, less toxicity, and effective silencing. Furthermore, the disulfide bridge can be reduced in the presence of glutathione, possibly releasing encapsulated siRNA in the peptide/siRNA complex.</p><p id="p-0016" num="0015">Various objects, features, aspects, and advantages of the subject matter disclosed herein will become more apparent from the following detailed description of preferred embodiments, along with the accompanying drawing figures in which like numerals represent like components.</p><p id="p-0017" num="0016">One should appreciate that the disclosed techniques provide many advantageous technical effects, including the efficient and direct introduction of nucleic acids (such as siRNA) into living cells.</p><?summary-of-invention description="Summary of Invention" end="tail"?><?brief-description-of-drawings description="Brief Description of Drawings" end="lead"?><description-of-drawings><heading id="h-0005" level="1">BRIEF DESCRIPTION OF THE FIGURES</heading><p id="p-0018" num="0017"><figref idref="DRAWINGS">FIG. <b>1</b></figref>. Cyclic peptides containing alternative tryptophan and arginine residues, [WR]<sub>4 </sub>(SEQ ID NO.: 2) and [WR]<sub>5 </sub>(SEQ ID NO.: 1) (Nasrolahi Shirazi et al., 2014; Mozaffari et al., 2019).</p><p id="p-0019" num="0018"><figref idref="DRAWINGS">FIG. <b>2</b></figref>. Chemical structures of linear peptide-fatty acid conjugates reported by us (Do et at, 2017),</p><p id="p-0020" num="0019"><figref idref="DRAWINGS">FIG. <b>3</b></figref>. Fatty acyl conjugates of cyclic peptides previously reported by us (Do et al., 2017),</p><p id="p-0021" num="0020"><figref idref="DRAWINGS">FIG. <b>4</b></figref>, Chemical structures of class I peptides (Class I: cyclic and linear peptides containing alternative tryptophan and arginine residues and two cysteines).</p><p id="p-0022" num="0021"><figref idref="DRAWINGS">FIG. <b>5</b></figref>. Chemical structures of class 2 peptides: cyclic peptides containing tryptophan residues in one side and arginine residues on another side and two cysteines).</p><p id="p-0023" num="0022"><figref idref="DRAWINGS">FIG. <b>6</b></figref>. Chemical structures of class 3 peptides: linear and cyclic-linear peptides containing two chains of hydrophobic tryptophan residues attached to polyarginine linear peptides or cyclic peptides containing arginine residues through cysteine residues.</p><p id="p-0024" num="0023"><figref idref="DRAWINGS">FIG. <b>7</b></figref>. Chemical structures of class 3 peptides: cyclic-linear peptides containing two chains of hydrophobic tryptophan residues attached to polyarginine linear peptides or cyclic peptides containing arginine residues through lysine residues.</p><p id="p-0025" num="0024"><figref idref="DRAWINGS">FIG. <b>8</b></figref>. Synthesis of linear and cyclic peptide cyclized through a disulfide bridge.</p><p id="p-0026" num="0025"><figref idref="DRAWINGS">FIG. <b>9</b></figref>. A representative example of synthesis of the cyclic peptide ([CR<sub>5</sub>W<sub>5</sub>C] (SEQ ID NO.: 4)).</p><p id="p-0027" num="0026"><figref idref="DRAWINGS">FIG. <b>10</b></figref>. The formation of peptide-capped gold nanoparticles (Peptide-AuNPs) from the reaction of peptides with HAuCl<sub>4</sub>.</p><p id="p-0028" num="0027"><figref idref="DRAWINGS">FIG. <b>11</b></figref>. the formation of gold nanoparticles by compounds in class 4 ([W<sub>4</sub>-&#x3b2;-Ala-R<sub>4</sub>-&#x3b2;-Ala] (SEQ ID NO.: 5) and (W<sub>4</sub>-&#x3b2;Ala-R<sub>4</sub>-&#x3b2;Ala) (SEQ ID NO.: 6). The synthesis of gold nanoparticles is monitored by UV-vis spectroscopy. The appearance of the absorbance band at 530 nm confirms the synthesis of gold nanoparticles.</p><p id="p-0029" num="0028"><figref idref="DRAWINGS">FIG. <b>12</b></figref>. The formation of gold nanoparticles by compounds in class 4 ([W<sub>4</sub>-(&#x3b2;Ala)<sub>2</sub>-R<sub>4</sub>-(&#x3b2;Ala)<sub>2</sub>] (SEQ ID NO.: 7) and W<sub>4</sub>-(&#x3b2;Ala)<sub>2</sub>-R<sub>4</sub>-(&#x3b2;Ala)<sub>2</sub>(SEQ ID NO.: 8)),</p><p id="p-0030" num="0029"><figref idref="DRAWINGS">FIG. <b>13</b></figref>. Overview of the synthetic scheme for the synthesis of pegylated cell-penetrating peptide (PEG-CPP), Pegylated targeting peptide (PEG-TP) composed of cyclic RGD, and final conjugate (TP-PEG-CPP) (targeting peptide=TP=RGDdFK (SEQ ID NO.: 9)).</p><p id="p-0031" num="0030"><figref idref="DRAWINGS">FIG. <b>14</b></figref>. Serum stability of siRNA after complex formation. Representative image of gel electrophoresis and bar graph summarizing the percentage of intact siRNA after 24 h exposure to serum (25%) at 37&#xb0; C.</p><p id="p-0032" num="0031"><figref idref="DRAWINGS">FIG. <b>15</b></figref>. The serum stability of siRNA complexed with lead peptides as compared to &#x201c;naked&#x201d; siRNA.</p><p id="p-0033" num="0032"><figref idref="DRAWINGS">FIG. <b>16</b></figref>. A graph showing cytotoxicity of peptide/siRNA complexes in MBA-MB-231 breast cancer cells. Neither of the peptides showed significant toxicity in the range of concentration or N/P ratio evaluated.</p><p id="p-0034" num="0033"><figref idref="DRAWINGS">FIG. <b>17</b></figref>. Cell viability of the peptides and the peptide/siRNA complexes in MDA-MB-231 cells after 48 h incubation.</p><p id="p-0035" num="0034"><figref idref="DRAWINGS">FIG. <b>18</b></figref>. A graph showing cell uptake of led siRNA/peptide complexes at an N/P ratio of 20 compared to Lipofectamine&#x2122; 2000 (Lipo.).</p><p id="p-0036" num="0035"><figref idref="DRAWINGS">FIG. <b>19</b></figref>. Cellular uptake of FAM-siRNA in MDA-MB-231 cells. The internalization of FAM-labeled siRNA into MDA-MB-231 after 24 h. Right panels in each set of peptides are presented as the percentage of the cells positive for siRNA uptake. The average of the fluorescence in the cell population is shown in the left panel. The cells were transfected by peptide/siRNA complex at an N/P ratio of 40. Data are presented as mean, n=3, and error bars represent standard deviation.</p><p id="p-0037" num="0036"><figref idref="DRAWINGS">FIG. <b>20</b></figref>. siRNA uptake using gold nanoparticles generated by linear peptide R<sub>4</sub>-&#x3b2;Ala-W<sub>4</sub>-&#x3b2;-Ala (SEQ ID NO.: 10).</p><p id="p-0038" num="0037"><figref idref="DRAWINGS">FIG. <b>21</b></figref>. siRNA uptake using gold nanoparticles generated by linear peptide R<sub>4</sub>-(&#x3b2;Ala)<sub>2</sub>-W<sub>4</sub>-(&#x3b2;Ala)<sub>2 </sub>((SEQ ID NO.: 11)</p><p id="p-0039" num="0038"><figref idref="DRAWINGS">FIG. <b>22</b></figref>. A group of micrographs showing uptake of siRNA/'peptide complexes (N/P 20) by confocal microscopy.</p><p id="p-0040" num="0039"><figref idref="DRAWINGS">FIG. <b>23</b></figref>. Silencing of Stat3 with peptides (Western blot analysis).</p><p id="p-0041" num="0040"><figref idref="DRAWINGS">FIG. <b>24</b></figref>. Silencing of Stat3 by peptides.</p><p id="p-0042" num="0041"><figref idref="DRAWINGS">FIG. <b>25</b></figref>. Transfection with gold nanoparticles generated with linear R<sub>4</sub>w<sub>4 </sub>(SEQ ID NO.: 12) and R<sub>5</sub>W<sub>5</sub>(SEQ ID NO.: 13) in MDA-MB-231 cells.</p><p id="p-0043" num="0042"><figref idref="DRAWINGS">FIG. <b>26</b></figref>. Transfection with gold nanoparticles generated with linear R<sub>4</sub>-&#x3b2;-Ala-W<sub>4</sub>-&#x3b2;-Ala (SEQ ID NO.: 10) and R<sub>4</sub>-&#x3b2;Ala)<sub>2</sub>-W<sub>4</sub>-(&#x3b2;-Ala)<sub>2 </sub>(SEQ ID NO.: 11) in MDA-MB-231 cells.</p><p id="p-0044" num="0043"><figref idref="DRAWINGS">FIG. <b>27</b></figref>. Silencing of Stat3 with peptides (Western blot analysis).</p><p id="p-0045" num="0044"><figref idref="DRAWINGS">FIG. <b>28</b></figref>. Silencing of Src with peptides (Western blot analysis).</p><p id="p-0046" num="0045"><figref idref="DRAWINGS">FIG. <b>29</b></figref>. Transfection of HEK293 cells with GFP plasmid using Lipofectamine (positive control) and selected peptides. Images were prepared using fluorescent microscope 48 hours after transfection. The toxicity of lipofectamine is observed as detachment of the cells, which creates aggregates of floating cells in the media.</p></description-of-drawings><?brief-description-of-drawings description="Brief Description of Drawings" end="tail"?><?detailed-description description="Detailed Description" end="lead"?><heading id="h-0006" level="1">DETAILED DESCRIPTION</heading><p id="p-0047" num="0046">Although each embodiment represents a single combination of inventive elements, the disclosed subject matter is considered to include all possible combinations of the disclosed elements. Thus, if one embodiment comprises elements A, B, and C, and a second embodiment comprises elements B and D, then other remaining combinations of A, B, C, or D, are considered disclosed and contemplated even if not explicitly disclosed.</p><p id="p-0048" num="0047">In some embodiments, the numbers expressing quantities of ingredients, properties such as concentration, reaction conditions, and so forth, used to describe and claim certain embodiments of the invention are to be understood as being modified in some instances by the term &#x201c;about.&#x201d; Accordingly, in some embodiments, the numerical parameters set forth in the written description and attached claims are approximations that can vary depending upon the desired properties sought to be obtained by a particular embodiment. In some embodiments, the numerical parameters should be construed in light of the number of reported significant digits and by applying ordinary rounding techniques. Notwithstanding that the numerical ranges and parameters setting forth the broad scope of some embodiments of the invention are approximations, the numerical values set forth in the specific examples are reported as precisely as practicable, The numerical values presented in some embodiments of the invention may contain certain errors necessarily resulting from the standard deviation found in their respective testing measurements.</p><p id="p-0049" num="0048">As used in the description herein and throughout the claims that follow, the meaning of &#x201c;a,&#x201d; &#x201c;an,&#x201d; and &#x201c;the&#x201d; includes plural reference unless the context clearly dictates otherwise. Also, as used in the description herein, the meaning of &#x201c;in&#x201d; includes &#x201c;in&#x201d; and &#x201c;on&#x201d; unless the context clearly dictates otherwise.</p><p id="p-0050" num="0049">Throughout the description and claims of this specification the word &#x201c;comprise&#x201d; and other forms of the word, such as &#x201c;comprising&#x201d; and &#x201c;comprises,&#x201d; means including but not limited to, and is not intended to exclude, for example, other additives, components, integers, or steps.</p><p id="p-0051" num="0050">As used herein, the terms &#x201c;optional&#x201d; or &#x201c;optionally&#x201d; means that the subsequently described event or circumstance can or cannot occur and that the description includes instances where said event or circumstance occurs and instances where it does not.</p><p id="p-0052" num="0051">The recitation of ranges of values herein is merely intended to serve as a shorthand method of referring individually to each separate value falling within the range. Unless otherwise indicated herein, each individual value is incorporated into the specification as if it were individually recited herein. All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g., &#x201c;such as&#x201d;) provided with respect to certain embodiments herein is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention otherwise claimed. No language in the specification should be construed as indicating any non-claimed element essential to the practice of the invention.</p><p id="p-0053" num="0052">The term &#x201c;hybrid peptide&#x201d; is used to represent a peptide, which consists of a combination of linear and cyclic peptides. The peptide library was screened for their biophysiochemical properties, such as binding affinity for siRNA, particle size and surface charges of peptide/siRNA complex, and the stability of the complex in the presence of serum, and the siRNA release profile to establish a structure-function relationship.</p><p id="p-0054" num="0053">Groupings of alternative elements or embodiments of the invention disclosed herein are not to be construed as limitations. Each group member can be referred to and claimed individually or in any combination with other members of the group or other elements found herein. One or more members of a group can be included in, or deleted from, a group for reasons of convenience and/or patentability. When any such inclusion or deletion occurs, the specification is herein deemed to contain the group as modified, thus fulfilling the written description of all Markush groups used in the appended claims.</p><p id="p-0055" num="0054">Compositions</p><p id="p-0056" num="0055">The first class of peptides contains positively charged amino acids (e.g.) arginine and hydrophobic amino acids (e.g., tryptophan residues) in an alternating fashion, where the peptide is cyclized through a disulfide linkage of two cysteine residues positioned at the IV- and C-termini of a linear precursor peptide (<figref idref="DRAWINGS">FIG. <b>4</b></figref>), It should be appreciated that such an arrangement introduces a disulfide bond into the primary ring structure of the cyclic peptide.</p><p id="p-0057" num="0056">Class 1 includes [C(RW)<sub>n</sub>C]; wherein n=1-10. The increase in positive charge density and hydrophobicity will enhance optimal interaction with siRNA by modulating R and W residues (alternate or R on one side and W on opposite side) between the disulfide bridges. To demonstrate the role of the disulfide bridge in the release of nucleic acid from the peptide/siRNA complexes, the linear and amide derivatives of peptides (replacement of both C amino acids with glutamic acid (E) and lysine (K) residues to form amide bridge) were also synthesized.</p><p id="p-0058" num="0057">A second class of compounds (<figref idref="DRAWINGS">FIG. <b>5</b></figref>) includes cyclic peptides containing hydrophobic amino acids (e.g., tryptophan residues) in one block or segment and positively charged amino acids (e.g., arginine residues) in another block or segment, as well as two cysteines (for example, positioned at the N- and C-termini) that can be free or utilized for cyclization via disulfide formation. Class 2 includes peptides [CR<sub>a</sub>W<sub>b</sub>C]; wherein a=1-10, b=1-10. The number of arginine and tryptophan residues can range from 1 to 10. Alternatively, this class of peptides includes peptides [R<sub>a</sub>W<sub>b</sub>] composed of with R residues on one side and hydrophobic W residues on the other side, and the peptides are cyclized using N- to C-terminal cyclization ([R<sub>a</sub>W<sub>b</sub>] where a=1-10, b=1-10).</p><p id="p-0059" num="0058">A third class of peptides (<figref idref="DRAWINGS">FIG. <b>6</b></figref>) includes linear peptides containing two linear chains of hydrophobic amino acids (e.g., tryptophan residues) attached to a linear poly-positively charged amino acid (e.g., polyarginine) segment to form linear peptides or hybrid cyclic-linear peptides containing cyclic poly-positively charged amino acid (e.g., polyarginine) cyclized through a disulfide linkage and linked to two linear chains of hydrophobic amino acid (e.g., tryptophan) residues. The third class of peptides also includes hybrid cyclic-linear peptides containing cyclic poly-positively charged amino acid (e.g., polyarginine) residues cyclized through an amide linkage and linked to two chains of hydrophobic amino acid (e.g., tryptophan) residues through lysine residues (<figref idref="DRAWINGS">FIG. <b>7</b></figref>).</p><p id="p-0060" num="0059">This class of peptides W<sub>x</sub>[CR<sub>y</sub>C]W<sub>x </sub>or (Rx[CW<sub>y</sub>C]R<sub>x </sub>where x=1-10, y=1-10) is based on the lead peptide W<sub>4</sub>[CR<sub>5</sub>C]W<sub>4</sub>(SEQ ID NO.: 14). The optimal balance of hydrophobicity was achieved with optimizing linear chains of residues and R residues in the cyclic component in this class of peptides.</p><p id="p-0061" num="0060">Alternatively, the corresponding linear peptides (W)<sub>n</sub>(KR<sub>n</sub>K)(W)<sub>n </sub>and (W)<sub>n</sub>(R<sub>n</sub>)(W)<sub>n </sub>can be included in this group. The number of positively charged (e.g., arginine) and hydrophobic (e.g., tryptophan) residues can range from 1 to 10.</p><p id="p-0062" num="0061">The fourth class of compounds composed of linear and cyclic peptides containing positively-charged residues such as arginine and hydrophobic residues such as tryptophan separated from each other by beta alanine (W<sub>4</sub>(&#x3b2;-alanine)<sub>x</sub>-R<sub>n</sub>-(&#x3b2;-alanine)<sub>x </sub>where n=1-10, and x=1-5. Examples of compounds in this group are [W<sub>4</sub>-&#x3b2;Ala-R<sub>4</sub>-&#x3b2;Ala] (SEQ ID NO.: 5) and (W<sub>4</sub>-&#x3b2;Ala-R<sub>4</sub>-&#x3b2;Ala) ((SEQ ID NO.: 6)).</p><p id="p-0063" num="0062">Fourth classes of compounds can be used alone for nucleic acid delivery or be used for the generation of peptide-capped gold nanoparticles that are used for nucleic acid delivery.</p><p id="p-0064" num="0063">The peptides (see examples in Table 1) were synthesized using Fmoc/tBu solid-phase synthesis. In brief, the linear peptides were assembled on trityl resin. The amino acids in the sequence were conjugated using Fmoc-amino acid building blocks in the presence of 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU), and diisopropylethylamine (DIPEA) in dimethylformamide (DMF). After each coupling, the Fmoc deprotection performed using 20% (v/v) piperidine in DMF. The progress of the reaction was monitored by matrix-assisted laser desorption/ionization (MALI) time-of-flight (TOF) analyzer. The resultant peptides were cleaved from the resin, followed by purification and lyophilization. The linear peptides containing cysteine residues were oxidized in the presence of 10% DMSO/Water to introduce disulfide bridges. The amide bridged derivative was synthesized by using orthogonal protecting K and E residues that are selectively deprotected on a solid support to form an amide bridge in the side chains followed by complete deprotection and purification.</p><p id="p-0065" num="0000"><tables id="TABLE-US-00001" num="00001"><table frame="none" colsep="0" rowsep="0" pgwide="1"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="280pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 1</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Representation of the composition of classes 1-4 peptides.</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="6"><colspec colname="1" colwidth="42pt" align="center"/><colspec colname="2" colwidth="42pt" align="center"/><colspec colname="3" colwidth="35pt" align="center"/><colspec colname="4" colwidth="56pt" align="center"/><colspec colname="5" colwidth="42pt" align="center"/><colspec colname="6" colwidth="63pt" align="center"/><tbody valign="top"><row><entry/><entry/><entry/><entry/><entry/><entry>Class 4</entry></row><row><entry/><entry>Class 2</entry><entry>Class 2</entry><entry>Class 3</entry><entry>Class 3</entry><entry>[W<sub>n</sub>(&#x3b2;<sub>4</sub>-alanine)<sub>x</sub>-</entry></row><row><entry>Class 1</entry><entry>[CR<sub>a</sub>W<sub>b</sub>C]</entry><entry>[R<sub>a</sub>W<sub>b</sub>]</entry><entry>W<sub>x</sub>[CR<sub>y</sub>C]W<sub>x</sub></entry><entry>R<sub>x</sub>[CW<sub>y</sub>C]R<sub>x</sub></entry><entry>R<sub>n</sub>(&#x3b2;-alanine)<sub>x</sub>] </entry></row><row><entry>[C(RW)<sub>n</sub>C]</entry><entry>a = 1-10, </entry><entry>a = 1-10,</entry><entry>x = 1-10, </entry><entry>x = 1-10, </entry><entry>n = 1-10, and</entry></row><row><entry>n = 1-10</entry><entry>b = 1-10&#x2009;</entry><entry>b = 1-10&#x2009;</entry><entry>y = 1-10&#x2009;</entry><entry>y = 1-10&#x2009;</entry><entry>x = 1-5</entry></row><row><entry namest="1" nameend="6" align="center" rowsep="1"/></row><row><entry>[C(RW)<sub>3</sub>C]</entry><entry>[CR<sub>4</sub>W<sub>4</sub>C]</entry><entry>[R<sub>4</sub>W<sub>4</sub>]</entry><entry>W<sub>2</sub>[CR<sub>5</sub>C]W<sub>2</sub></entry><entry>R<sub>2</sub>[CW<sub>5</sub>C]R<sub>2</sub></entry><entry>[W<sub>5</sub>-&#x3b2;Ala-R<sub>5</sub>-&#x3b2;Ala]</entry></row><row><entry>(SEQ ID</entry><entry>(SEQ ID</entry><entry>(SEQ ID</entry><entry>(SEQ ID </entry><entry>(SEQ ID </entry><entry>(SEQ ID</entry></row><row><entry>NO.: 15)</entry><entry>NO.: 16)</entry><entry>NO.: 12)</entry><entry>NO.: 17)</entry><entry>NO.: 18)</entry><entry>NO.: 19)</entry></row><row><entry>[C(RW)<sub>4</sub>C]</entry><entry>[CR<sub>5</sub>W<sub>4</sub>C]</entry><entry>[R<sub>5</sub>W<sub>4</sub>]</entry><entry>W<sub>2</sub>[CR<sub>6</sub>C]W<sub>2</sub></entry><entry>R<sub>2</sub>[CW<sub>6</sub>C]R<sub>2</sub></entry><entry>[W<sub>4</sub>-&#x3b2;Ala-R<sub>4</sub>-&#x3b2;Ala]</entry></row><row><entry>(SEQ ID</entry><entry>(SEQ ID</entry><entry>(SEQ ID</entry><entry>(SEQ ID </entry><entry>(SEQ ID </entry><entry>(SEQ ID</entry></row><row><entry>NO.: 20)</entry><entry>NO.: 21)</entry><entry>NO.: 22</entry><entry>NO.: 23)</entry><entry>NO.: 24)</entry><entry>NO.: 5)</entry></row><row><entry>[C(RW)<sub>5</sub>C]</entry><entry>[CR<sub>6</sub>W<sub>4</sub>C]</entry><entry>[R<sub>6</sub>W<sub>4</sub>]</entry><entry>W<sub>2</sub>[CR<sub>7</sub>C]W<sub>2</sub></entry><entry>R<sub>2</sub>[CW<sub>7</sub>C]R<sub>2</sub></entry><entry>[W<sub>3</sub>-&#x3b2;Ala-R<sub>3</sub>-&#x3b2;Ala]</entry></row><row><entry>(SEQ ID</entry><entry>(SEQ ID</entry><entry>(SEQ ID</entry><entry>(SEQ ID </entry><entry>(SEQ ID </entry><entry>(SEQ ID</entry></row><row><entry>NO.: 25)</entry><entry>NO.: 26)</entry><entry>NO.: 27)</entry><entry>NO.: 28)</entry><entry>NO.: 29)</entry><entry>NO.: 30)</entry></row><row><entry>[C(RW)<sub>6</sub>C]</entry><entry>[CR<sub>7</sub>W<sub>4</sub>C]</entry><entry>[R<sub>7</sub>W<sub>4</sub>]</entry><entry>W<sub>3</sub>[CR<sub>5</sub>C]W<sub>3</sub></entry><entry>R<sub>3</sub>[CW<sub>5</sub>C]R<sub>3</sub></entry><entry>[W<sub>2</sub>-&#x3b2;Ala-R<sub>2</sub>-&#x3b2;Ala]</entry></row><row><entry>(SEQ ID</entry><entry>(SEQ ID</entry><entry>(SEQ ID</entry><entry>(SEQ ID </entry><entry>(SEQ ID </entry><entry>(SEQ ID</entry></row><row><entry>NO.: 31)</entry><entry>NO.: 32)</entry><entry>NO.: 33)</entry><entry>NO.: 34)</entry><entry>NO.: 35)</entry><entry>NO.: 36)</entry></row><row><entry>[C(RW)<sub>7</sub>C]</entry><entry>[CR<sub>4</sub>W<sub>5</sub>C]</entry><entry>[R<sub>4</sub>W<sub>5</sub>]</entry><entry>W<sub>3</sub>[CR<sub>6</sub>C]W<sub>3</sub></entry><entry>R<sub>3</sub>[CW<sub>6</sub>C]R<sub>3</sub></entry><entry>[W<sub>4</sub>-&#x3b2;Ala<sub>2</sub>-R<sub>4</sub>-&#x3b2;Ala<sub>2</sub>]</entry></row><row><entry>(SEQ ID</entry><entry>(SEQ ID</entry><entry>(SEQ ID</entry><entry>(SEQ ID </entry><entry>(SEQ ID </entry><entry>(SEQ ID</entry></row><row><entry>NO.: 37)</entry><entry>NO.: 38)</entry><entry>NO.: 39)</entry><entry>NO.: 40)</entry><entry>NO.: 41)</entry><entry>NO.: 42)</entry></row><row><entry>[C(RW)<sub>8</sub>C]</entry><entry>[CR<sub>4</sub>W<sub>6</sub>C]</entry><entry>[R<sub>4</sub>W<sub>6</sub>]</entry><entry>W<sub>3</sub>[CR<sub>7</sub>C]W<sub>3</sub></entry><entry>R<sub>3</sub>[CW<sub>7</sub>C]R<sub>3</sub></entry><entry>[W<sub>5</sub>-&#x3b2;Ala-R<sub>5</sub>-&#x3b2;Ala]</entry></row><row><entry>(SEQ ID</entry><entry>(SEQ ID</entry><entry>(SEQ ID</entry><entry>(SEQ ID </entry><entry>(SEQ ID </entry><entry>(SEQ ID</entry></row><row><entry>NO.: 43)</entry><entry>NO.: 44)</entry><entry>NO.: 45)</entry><entry>NO.: 46)</entry><entry>NO.: 47)</entry><entry>NO.: 48)</entry></row><row><entry>[C(RW)<sub>9</sub>C]</entry><entry>[CR<sub>4</sub>W<sub>7</sub>C]</entry><entry>[R<sub>4</sub>W<sub>7</sub>]</entry><entry>W<sub>4</sub>[CR<sub>5</sub>C]W<sub>4</sub></entry><entry>R<sub>4</sub>[CW<sub>5</sub>C]R<sub>4</sub></entry><entry>[W<sub>4</sub>-&#x3b2;Ala-R<sub>4</sub>-&#x3b2;Ala]</entry></row><row><entry>(SEQ ID</entry><entry>(SEQ ID</entry><entry>(SEQ ID</entry><entry>(SEQ ID </entry><entry>(SEQ ID </entry><entry>(SEQ ID</entry></row><row><entry>NO.: 49)</entry><entry>NO.: 50)</entry><entry>NO.: 51)</entry><entry>NO.: 52)</entry><entry>NO.: 53)</entry><entry>NO.: 54)</entry></row><row><entry>[C(RW)<sub>10</sub>C]</entry><entry>[CR<sub>5</sub>W<sub>5</sub>C]</entry><entry>[R<sub>5</sub>W<sub>5</sub>]</entry><entry>W<sub>4</sub>[CR<sub>6</sub>C]W<sub>4</sub></entry><entry>R<sub>4</sub>[CW<sub>6</sub>C]R<sub>4</sub></entry><entry>[W<sub>3</sub>-&#x3b2;Ala-R<sub>3</sub>-&#x3b2;Ala]</entry></row><row><entry>(SEQ ID</entry><entry>(SEQ ID</entry><entry>(SEQ ID</entry><entry>(SEQ ID </entry><entry>(SEQ ID </entry><entry>(SEQ ID</entry></row><row><entry>NO.: 55)</entry><entry>NO.: 4)</entry><entry>NO.: 57)</entry><entry>NO.: 58)</entry><entry>NO.: 59)</entry><entry>NO.: 60)</entry></row><row><entry>[(RW)<sub>5</sub>]</entry><entry>[CR<sub>6</sub>W<sub>5</sub>C]</entry><entry>[R<sub>6</sub>W<sub>5</sub>]</entry><entry>W<sub>4</sub>[CR<sub>7</sub>C]W<sub>4</sub></entry><entry>R<sub>4</sub>[CW<sub>7</sub>C]R<sub>4</sub></entry><entry>[W<sub>2</sub>-&#x3b2;Ala-R<sub>2</sub>-&#x3b2;Ala]</entry></row><row><entry>(SEQ ID</entry><entry>(SEQ ID</entry><entry>(SEQ ID</entry><entry>(SEQ ID </entry><entry>(SEQ ID </entry><entry>(SEQ ID</entry></row><row><entry>NO.: 61)</entry><entry>NO.: 62)</entry><entry>NO.: 63)</entry><entry>NO.: 65)</entry><entry>NO.: 65)</entry><entry>NO.: 66)</entry></row><row><entry>[K(RW)<sub>5</sub>E]</entry><entry>[CR<sub>7</sub>W<sub>5</sub>C]</entry><entry>[R<sub>7</sub>W<sub>5</sub>]</entry><entry>W<sub>5</sub>[CR<sub>5</sub>C]W<sub>5</sub></entry><entry>R<sub>5</sub>[CW<sub>5</sub>C]R<sub>5</sub></entry><entry>[W<sub>4</sub>-&#x3b2;Ala<sub>2</sub>-R<sub>4</sub>-&#x3b2;Ala<sub>2</sub>]</entry></row><row><entry>(SEQ ID</entry><entry>(SEQ ID</entry><entry>(SEQ ID</entry><entry>(SEQ ID </entry><entry>(SEQ ID </entry><entry>(SEQ ID</entry></row><row><entry>NO.: 67)</entry><entry>NO.: 68)</entry><entry>NO.: 69)</entry><entry>NO.: 70)</entry><entry>NO.: 71)</entry><entry>NO.: 72)</entry></row><row><entry>Linear</entry><entry>[CR<sub>5</sub>W<sub>6</sub>C]</entry><entry>[R<sub>5</sub>W<sub>6</sub>]</entry><entry>W<sub>5</sub>[CR<sub>6</sub>C]W<sub>5</sub></entry><entry>R<sub>5</sub>[CW<sub>5</sub>C]R<sub>5</sub></entry><entry/></row><row><entry>(C(RW)<sub>n</sub>C</entry><entry>(SEQ ID</entry><entry>(SEQ ID</entry><entry>(SEQ ID </entry><entry>(SEQ ID </entry><entry/></row><row><entry/><entry>NO.: 73)</entry><entry>NO.: 74)</entry><entry>NO.: 75)</entry><entry>NO.: 76)</entry><entry/></row><row><entry/><entry>[CR<sub>5</sub>W<sub>7</sub>C]</entry><entry>[R<sub>5</sub>W<sub>7</sub>]</entry><entry>W<sub>5</sub>[CR<sub>7</sub>C]W<sub>5</sub></entry><entry>R<sub>5</sub>[CW<sub>7</sub>C]R<sub>5</sub></entry><entry/></row><row><entry/><entry>(SEQ ID</entry><entry>(SEQ ID</entry><entry>(SEQ ID </entry><entry>(SEQ ID </entry><entry/></row><row><entry/><entry>NO.: 77)</entry><entry>NO.: 78)</entry><entry>NO.: 79)</entry><entry>NO.: 80)</entry><entry/></row><row><entry/><entry>[CR<sub>6</sub>W<sub>6</sub>C]</entry><entry>[R<sub>6</sub>W<sub>6</sub>]</entry><entry>(W)<sub>n</sub>[KR<sub>7</sub>K](W)<sub>n</sub></entry><entry>Linear</entry><entry/></row><row><entry/><entry>(SEQ ID</entry><entry>(SEQ ID</entry><entry/><entry>R<sub>n</sub>CW<sub>n</sub>CR<sub>n</sub></entry><entry/></row><row><entry/><entry>NO.: 81)</entry><entry>NO.: 82)</entry><entry/><entry/><entry/></row><row><entry/><entry>[CR<sub>7</sub>W<sub>7</sub>C]</entry><entry>[R<sub>7</sub>W<sub>7</sub>]</entry><entry>Linear</entry><entry/><entry/></row><row><entry/><entry>(SEQ ID</entry><entry>(SEQ ID</entry><entry>W<sub>n</sub>CR<sub>n</sub>CW<sub>n</sub></entry><entry/><entry/></row><row><entry/><entry>NO.: 83)</entry><entry>NO.: 84)</entry><entry/><entry/><entry/></row><row><entry/><entry>[CR<sub>8</sub>W<sub>8</sub>C]</entry><entry>[R<sub>8</sub>W<sub>8</sub>]</entry><entry>Linear</entry><entry/><entry/></row><row><entry/><entry>(SEQ ID</entry><entry>(SEQ ID</entry><entry>(W)<sub>n</sub>(KR<sub>n</sub>K)(W)<sub>n</sub></entry><entry/><entry/></row><row><entry/><entry>NO.: 85)</entry><entry>NO.: 86)</entry><entry/><entry/><entry/></row><row><entry/><entry>[CR<sub>9</sub>W<sub>9</sub>C]</entry><entry>[R<sub>9</sub>W<sub>9</sub>]</entry><entry>(Linear</entry><entry/><entry/></row><row><entry/><entry>(SEQ ID</entry><entry>(SEQ ID</entry><entry>W)<sub>n</sub>(R<sub>n</sub>)(W)<sub>n</sub></entry><entry/><entry/></row><row><entry/><entry>NO.: 87)</entry><entry>NO.: 88)</entry><entry/><entry/><entry/></row><row><entry/><entry>[CR<sub>10</sub>W<sub>10</sub>C]</entry><entry>[R<sub>10</sub>W<sub>10</sub>]</entry><entry/><entry/><entry/></row><row><entry/><entry>(SEQ ID</entry><entry>(SEQ ID</entry><entry/><entry/><entry/></row><row><entry/><entry>NO.: 89)</entry><entry>NO.: 90)</entry><entry/><entry/><entry/></row><row><entry/><entry>[KR<sub>4</sub>W<sub>4</sub>E]</entry><entry/><entry/><entry/><entry/></row><row><entry/><entry>(SEQ ID</entry><entry/><entry/><entry/><entry/></row><row><entry/><entry>NO.: 91)</entry><entry/><entry/><entry/><entry/></row><row><entry/><entry>[R<sub>n</sub>CW<sub>n</sub>C]</entry><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry/><entry><chemistry id="CHEM-US-00001" num="00001"><img id="EMI-C00001" he="7.37mm" wi="12.28mm" file="US20230000999A1-20230105-C00001.TIF" alt="embedded image" img-content="table" img-format="tif"/></chemistry></entry><entry/><entry/><entry/><entry/></row><row><entry> </entry></row><row><entry/><entry><chemistry id="CHEM-US-00002" num="00002"><img id="EMI-C00002" he="7.45mm" wi="12.78mm" file="US20230000999A1-20230105-C00002.TIF" alt="embedded image" img-content="table" img-format="tif"/></chemistry></entry></row><row><entry namest="1" nameend="6" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0066" num="0064">Linear, cyclic, hybrid cyclic-linear peptides were synthesized that have hydrophobic positively-charged, and/or cysteine residues as the amino acid sequence in its basic structure. Inventors varied the amino acid constituents in the structure to determine the effectiveness of derived compounds in siRNA binding and delivery and to establish a structure-activity relationship. The strategy was to vary net hydrophobicity and the positive charges of derived compounds based on structure-activity relationships and evaluate siRNA binding, delivery, and silencing potentials. The rationale of current studies was that cancer cells have a higher percentage of glutathione relative to normal cells. Accordingly, disulfide bonds can be reduced in cancer cells to a significantly higher degree than normal cells, providing selective delivery of siRNA to cancer cells.</p><p id="p-0067" num="0065">Compounds disclosed herein represent a new class of transfection delivery agents. The structures of these series of compounds are different than those of current delivery agents. The used amino acids, peptide sequence, examples of their structures, in vitro siRNA binding affinity, cytotoxicity, siRNA delivery, and silencing potential are summarized herein.</p><p id="p-0068" num="0066">Preferred compound(s) could be used as a stand-alone or to be used in generating peptide-capped gold or silver nanoparticles for siRNA delivery. These peptides can be used in combination with siRNA. in different ratios. Alternatively, peptide-capped nanoparticles of these peptides can be combined with siRNA. The peptides can be used alone or in combination with nanoparticles and peptide-capped nanoparticles. Examples of suitable nanoparticles include metal nanoparticles (e.g., gold and/or silver nanoparticles) that can be used in combination with peptides to improve the delivery of siRNA. Cell-penetrating peptide-capped nanoparticles with antimicrobial properties will be preferentially taken up by the cells where they gradually release their cargo siRNA, resulting in sustained local silencing effect by a two-pronged mechanism without causing significant toxicity to normal cells. Peptides-capped metal nanoparticles have cell-penetrating properties as membrane permeabilizers. Cell-penetrating peptides can entrap siRNA. and enhance the uptake of siRNA across the membrane when they cap the metal nanoparticles.</p><p id="p-0069" num="0067">Compounds disclosed herein represent a new class of nucleic delivery agents. The structures of these series of compounds are different than those of current delivery agents. The used amino acids, peptide sequence, examples of their structures, in vitro siRNA binding affinity, cytotoxicity, siRNA delivery, and silencing potential are summarized herein.</p><p id="p-0070" num="0068">Amino acids: Examples of suitable positively-charged amino acids in the linear and cyclic peptides are L-arginine, L-lysine, L-histidine, D-histidine, D-arginine, D-lysine. Furthermore, positively-charged amino acids are L- or D-arginine and L- or D-lysine, ornithine, L- or D-histidine residues with shorter or longer side chains (e.g., C3-Arginine (Agp), C4-Arginine (Agb)), diaminopropionic acid (Dap) and diaminobutyric acid (Dab), amino acids containing free side-chain amino or guanidine groups, and modified arginine and lysine residues.</p><p id="p-0071" num="0069">Examples of suitable hydrophobic residues in the linear and cyclic peptides are L-tryptophan, D-tryptophan, L-phenylalanine, D-phenylalanine, L-isoleucine, D-isoleucine, p-phenyl-L-phenylalanine (Bip), 3,3-diphenyl-L-alanine (Dip), 3(2-naphthyl)-L-alanine (NaI), 6-amino-2-naphthoic acid, 3-amino-2-naphthoic acid, 1,2,3,4-tetrahydronorharmane-3-carboxylic acid, 1,2,3,4-tetrahydro-3-isoquinolinecarboxylic acid (Tic-OH), 1,2,3,4-tetrahydro-3-isoquinolinecarboxylic acid, modified d- or 1-tryptophan residues like N-alkyl or N-aryl tryptophan, substituted d- or L-tryptophan residues (e.g., 5-hydroxy-L-tryptophan, 5-methoxy-L-tryptophan, 6-chloro-L-tryptophan), other N-heteroaromatic and hydrophobic amino acids, and fatty amino acids (e.g., NH<sub>2</sub>-(CH<sub>2</sub>),COOH, where x=1-20).</p><p id="p-0072" num="0070">Sequence: A preferred sequence of these peptides includes linear (C(XY)<sub>n</sub>C) or cyclic [(C(XY)<sub>n</sub>C)] (through disulfide bridge or N- to C-terminal or both), linear [C(X)<sub>n</sub>(Y)<sub>n</sub>C)] or cyclic [(C(X)<sub>n</sub>(Y)<sub>n</sub>)C)] (through disulfide bridge or N- to C-terminal or both), linear (Y)<sub>n</sub>CX<sub>n</sub>C(Y)<sub>n</sub>, (X)<sub>n</sub>CY<sub>n</sub>C(X)<sub>n </sub>or hybrid cyclic-linear (Y)<sub>n</sub>[CX<sub>n</sub>C](Y)<sub>n </sub>or hybrid cyclic-linear (X)<sub>n</sub>[CY<sub>n</sub>C](X)<sub>n </sub>or hybrid cyclic-linear (Y)<sub>n</sub>[KX<sub>n</sub>K](Y)<sub>n </sub>or hybrid cyclic-linear (X)<sub>n</sub>[KY<sub>n</sub>K](X)<sub>n </sub>or linear (X)<sub>n</sub>(KY<sub>n</sub>K)(X)<sub>n</sub>or linear (X)<sub>n</sub>(Y<sub>n</sub>)(X)<sub>n</sub>, wherein X is a positively-charged amino acid, Y is a hydrophobic residue or [X<sub>n</sub>-(&#x3b2;-alanaine)<sub>x</sub>-Y<sub>n</sub>-(&#x3b2;-alanaine)<sub>x</sub>], wherein n=1-10. Other amino acids can be inserted between positively-charged, between hydrophobic residues, or between positively-charged and hydrophobic residues while multiple positively-charged residues or multiple hydrophobic amino acids are next to each other, creating a positively-charged component on one side and a hydrophobic component on the other side. Similar or different positively charged or hydrophobic residues may be in the same peptide. In other words, positively charged amino acids can be the same or different. Similarly, hydrophobic amino acids in the same sequence can be the same or different. The peptides can have hybrid structures with cyclic peptides contain positively-charged residues or hydrophobic residues attached to two linear hydrophobic or positively-charged residues. Some of the sequences are shown in Table 1 and <figref idref="DRAWINGS">FIGS. <b>4</b>-<b>7</b></figref>.</p><p id="p-0073" num="0071">In some examples, peptides (cyclic [CR<sub>4</sub>W<sub>4</sub>C] (SEQ NO.: 16) and hybrid W:<sub>4</sub>[CR<sub>5</sub>C]W<sub>4</sub>) (SEQ ID NO.: 52) are disclosed; and other peptides in each group are inexpensive, easy-to-use, nontoxic, serum-stable, and efficient transfecting agent for all mammalian cells and in vitro nucleic acid delivery.</p><p id="p-0074" num="0072">In one aspect, disclosed are CPs and hybrid cyclic-linear peptides (HCLPs). The concept of using a cyclic peptide-based transfection agent will provide intrinsic property associated with a conformationally constrained structure, such as selectivity to a class of siRNA or cell line, stability, and protection to siRNA from nuclease and serum, and low toxicity. CPs and HCLPs synthesized from natural L-amino acid will be biodegradable, leading to minimum toxicity as compared to lipid or polymer-based transfection agents. The CPs-based transfection agent will be economical as compared to lipid or polymer-based transfecting agents. Structural design of the CPs in the proposed study originated after extensive modification of previously developed classes of CPs containing W and R residues in the cyclic ring ([WR]<sub>n</sub>; n=4,5) or R/W residues in the cyclic ring followed by a linear chain of R/W residues (called HCLPs: [R<sub>5</sub>K]W<sub>5 </sub>(SEQ ID NO.: 92) and [R<sub>6</sub>K]W<sub>6</sub>(SEQ ID NO.: 93)) or R residues in the cyclic ring containing chain of fatty acids ([(R<sub>5</sub>(K-C16)<sub>2</sub>], [R<sub>5</sub>(K-C18)<sub>2</sub>]) that demonstrate diverse applications in the non-covalent delivery of siRNA., By controlling and balancing inter-residue electrostatic and hydrophobic interactions with the siRNA. molecules, several classes of CPs and HCLPs were synthesized and evaluated with variable cellularization and efficiency in siRNA delivery. Efforts in structural modification provided several lead peptides (cyclic [CR<sub>4</sub>W<sub>4</sub>C] (SEQ ID NO.: 16) and hybrid W<sub>4</sub>[CR<sub>5</sub>C]W<sub>4</sub>(SEQ ID NO.: 52)), which demonstrated high transfection efficiency without toxicity, serum stability as compared to commercial agent lipofectamine. Lead peptide [CR<sub>4</sub>W<sub>4</sub>C] (SEQ ID NO.: 16) is cyclized through intramolecular disulfide bridge between cysteine residues, which seems important in the release of siRNA from peptide-siRNA. complex in the cytoplasm after being reduced with glutathione. The reduction of the disulfide bridge provides conformational changes in the peptide-siRNA. complex, which modulates the release of siRNA. Furthermore, these peptides are internalized independently of endocytic pathways, which is a significant and distinct property as compared to other drug delivery platforms. The unique and intrinsic property of lead peptides to spontaneously translocate across bilayers is distinct from the behavior of well-known, highly cationic CPPs, such as TAT and Arg<sub>9</sub>, which do not translocate across synthetic bilayers and instead enter cells primarily by endocytosis. Endosomal entrapment limits nucleic acid transfection efficiency significantly, as the nucleic acids are trapped in endocytic compartments and cannot reach their cytoplasmic or nuclear targets. The other significant advantage of the proposed structures is their high stability and low toxicity. Highly cationic CPPs preferentially interact with particular cell types, have limited serum half-life, show toxicity, and require 9-15 residues of R for efficient cargo delivery. Compared to linear CPPs, which are susceptible to hydrolysis by endogenous peptidases, cyclic peptides are enzymatically more stable and non-toxic. CPs and HCLPs can be used for different nucleic acids (including clustered regularly interspaced short palindromic repeats or CRISPR). Unlike many commercially available transfection agents that could not even be considered for in vivo use, the versatile structure of the proposed peptides offers the possibility of future modifications, e.g., incorporation into gold nanoparticles, conjugation with polyethylene glycol (PEG), and/or targeting moieties for stealth properties and active targeting, respectively, which create clinically relevant delivery systems.</p><p id="p-0075" num="0073">The peptides are amphipathic in nature and conformationally constrained due to the intramolecular disulfide bridge between cysteine residues (<figref idref="DRAWINGS">FIG. <b>4</b></figref>). Classes 1 and 2 comprise of the block (multiple residues) of R and W residues between two cysteines followed by a disulfide bridge, e.g., [CR<sub>4</sub>W<sub>4</sub>C] (SEQ ID NO.: 16), [C(RW)<sub>4</sub>C] (SEQ ID NO.: 20)) whereas Class 3 consists of two linear chains of hydrophobic residues on a cyclic peptide of R residues formed through a disulfide bridge, e.g., W<sub>4</sub>[CR<sub>5</sub>C]W<sub>4 </sub>(SEQ ID NO.: 52) or two linear chains of positively charged residues on a cyclic peptide of W residues formed through a disulfide bridge, e.g., R<sub>4</sub>[CW<sub>5</sub>C]R<sub>4 </sub>(SEQ ID NO.: 53). The R and W residues in Classes 1 and 2 could be alternate or all the R residues on one side and W residues on the opposite side, respectively. Class 2 also includes N to C cyclic peptides containing R and W residues with R residues on one side and W residues on the opposite side, e.g. [R4W<sub>4</sub>] ((SEQ ID NO.: 12). The lead peptides were synthesized using Fmoc/tBu solid-phase chemistry and fully characterized. Complexes were formed using scrambled siRNA and both peptides at a wide range of N/P ratios. The complexes formed with both peptides had a size of approximately 200 nm or lower and showed slightly positive zeta-potential, which increased at higher N/P ratios.</p><p id="p-0076" num="0074">The structural modifications in the lead peptides were used to optimize them as efficient vectors for cellular delivery of siRNA. through enhancing their interactions with negatively charged siRNA and providing them protection from the nucleases, and mediating the efficient cellular uptake.</p><p id="p-0077" num="0075">The balance of amphipathic character, density, and position of positive charges and hydrophobic moieties in the conformationally constrained structures of peptides generated an efficient transfecting agent.</p><p id="p-0078" num="0076">Classes 1 and 2 CPs contain disulfide and amide bridges and were developed to generate a conformationally constrained structure. Cyclic peptides are found to be more resistant to cellular metabolic enzymes, such as proteases and nucleases. Furthermore, the higher level of glutathione at the cellular level in various disease stages will facilitate the reduction of the disulfide bridge of peptide in the CPs containing disulfide bridge and thus changing the constrained conformation of the peptide to a flexible structure (a linear form of peptide), releasing the siRNA. Changes in the conformation of peptides in the peptide/siRNA complex will help in releasing the cargo inside the cytoplasm.</p><p id="p-0079" num="0077">The data indicated that the lead cyclic [CR<sub>4</sub>W<sub>4</sub>C] (SEQ ID NO.: 16) and hybrid W<sub>41</sub>[CR<sub>5</sub>C]W<sub>4 </sub>(SEQ ID NO.: 52) peptides containing disulfide bridge demonstrated potential applications as transfecting agents. Classes 1 and 2 peptides explore both the role of the disulfide bridge and constrained cyclic structure in developing optimal transfecting agents.</p><p id="p-0080" num="0078">Class 3 represents HCLP analogs, composed of hydrophobic linear chains attached to a cyclic peptide containing positively charged R residues or o linear chains of positively charged residues on a cyclic peptide of W residues.</p><heading id="h-0007" level="1">EXAMPLES</heading><p id="p-0081" num="0079">The following examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how the compounds, compositions, articles, devices, and/or methods claimed herein are made and evaluated and are intended to be purely exemplary of the invention and are not intended to limit the scope of what the inventors regard as their invention. However, those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments which are disclosed and still obtain a like or similar result without departing from the spirit and scope of the invention.</p><p id="p-0082" num="0080">Efforts have been made to ensure accuracy with respect to numbers (e.g., amounts, temperature, etc.), but some errors and deviations should be accounted for. Unless indicated otherwise, parts are parts by weight, the temperature is in &#xb0; C. or is at ambient temperature, and pressure is at or near atmospheric.</p><p id="p-0083" num="0081">The peptides can be used as pegylated peptides with or without targeting moieties such as RGD, folic acid, transferrin, antibody for nucleic acid delivery.</p><p id="p-0084" num="0082">All amino acid building blocks and preloaded amino acid on the resin used in this study were purchased from AAPPTEC. Other reagents, chemicals, and solvents were procured from Sigma-Aldrich. The final compounds used in further studies were purified with reversed-phase High-performance liquid chromatography from Shimadzu (LC-20AP) using a binary gradient system of acetonitrile 0.1% TFA and water 0.1% TEA and a reversed-phase preparative column (X Bridge BEH130 Prep C18, 10 &#x3bc;m 18&#xd7;250 &#x3bc;m Waters, Inc). The chemical structure of linear, cyclic, and hybrid cyclic-linear peptides, intermediates, and final products were characterized by high-resolution MALDI-TOF (GT-0264) from Broker Inc.</p><p id="p-0085" num="0083">General method for the synthesis of linear peptides. The synthesis of linear peptides was performed by Fmoc/tBu solid-phase peptide synthesis method. All the peptides were synthesized using Fmoc solid-phase peptide synthesis using appropriate resin and Fmoc-protected amino acids.</p><p id="p-0086" num="0084">Protected amino acid-2-Cl trityl resin and Fmoc protected amino acids were used as the building blocks for the synthesis peptides on a scale of 0.3 mmol. 2-H-benzotriazol -1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU)/N,N-diisopropylethylamine (DIPEA) were used as coupling and activating reagents, respectively. Piperidine in N,N-dimethylformamide (DMF) (20%, v/v) was used for Fmoc deprotection. The resultant peptides were cleaved from the resin, and all protecting groups were removed using a cleavage cocktail of TFA/anisole/EDT/thioanisole (90:5:3:2, v/v/v/v) for 3 h. Crude products were precipitated by the addition of cold diethyl ether purified by reverse phase HPLC using a gradient of 0-90% acetonitrile (0.1% TFA) and water (0.1% TFA) over 60 min with C-18 column. Purified peptides were lyophilized to yield a white powder. The chemical structures of all synthesized peptides were elucidated using matrix-assisted laser desorption/ionization (MALDI) time-of-flight (TOF) mass spectroscopy with &#x3b1;-cyano hydroxycinnamic acid (CHCA) as a matrix.</p><p id="p-0087" num="0085">MALDI-TOF (m/z) for C(RW)<sub>4</sub>C (SEQ ID NO.: 20) [C<sub>74</sub>H<sub>100</sub>N<sub>26</sub>O<sub>11</sub>S<sub>2</sub>]: calcd,1592.7506; found, 1592.7797 []<sup>&#x2212;</sup>; MALDI-TOF (m/z) for C(RW)<sub>5</sub>C (SEQ ID NO.: 94) [C<sub>91</sub>H<sub>122</sub>N<sub>32</sub>O<sub>13</sub>S<sub>2</sub>]: calcd,1934.9311; found, 1934.2925 [M]<sup>+</sup>; MALDI-TOF (m/z) for CR<sub>4</sub>C(SEQ ID NO.: 16) [C<sub>74</sub>H<sub>100</sub>N<sub>26</sub>O<sub>11</sub>S<sub>2</sub>]: calcd, 1592.7506; found, 1593.3369 [M+H]<sup>+</sup>; MALDI-TOF (m/z) for CR<sub>5</sub>W<sub>5</sub>C (SEQ ID NO.: 56) [C<sub>91</sub>H<sub>122</sub>N<sub>32</sub>O<sub>13</sub>S<sub>2</sub>]: calcd,1934,9311; found, 1936.445 [M+2H]<sup>+</sup>; MALDI-TOF (m/z) for R<sub>4</sub>CW<sub>4</sub>C (SEQ ID NO.: 95) [C<sub>74</sub>H<sub>100</sub>N<sub>26</sub>O<sub>11</sub>S<sub>2</sub>]: calcd, 1592.7506; found, 1593.957 [M+H]<sup>+</sup>; MALDI-TOF (m/z) for W<sub>4</sub>CR<sub>4</sub>C (SEQ ID NO.: 96) [C<sub>74</sub>H<sub>100</sub>N<sub>26</sub>O<sub>11</sub>S<sub>2</sub>]: calcd,1592.7506; found, 1593,160 [M+H]<sup>+</sup>; MALDI-TOF (m/z) for W<sub>2</sub>CR<sub>5</sub>CW<sub>2 </sub>(SEQ ID NO.: 97) [C<sub>80</sub>H<sub>112</sub>N<sub>30</sub>O<sub>12</sub>S<sub>2</sub>]: calcd, 1748.8517; found, 1749.475 [M+H]<sup>+</sup>; MALDI-TOF (m/z) for W<sub>3</sub>CR<sub>5</sub>CW<sub>3 </sub>(SEQ ID NO.: 98) [C<sub>102</sub>H<sub>132</sub>N<sub>34</sub>O<sub>14</sub>S<sub>2</sub>]: calcd, 2121.0104; found, 2122.159 [M+H]<sup>+</sup>; MALDI-TOF (m/z) for W<sub>4</sub>CR<sub>5</sub>CW<sub>4</sub>(SEQ ID NO.: 99) [C<sub>124</sub>H<sub>153</sub>N<sub>39</sub>O<sub>15</sub>D<sub>2</sub>]: calcd, 2493.1850; found, 2494.2889 [M+H]<sup>+</sup>.</p><p id="p-0088" num="0086">Synthesis of cyclic peptides through N- to C-cyclization. Amino acid loaded on trityl resin and Fmoc-amino acid building blocks were used for the synthesis on a scale of 0.3 mmol. HBTU/DIPEA was used as coupling and activating reagents, respectively. Piperidine DMF (20% v/v) was used for Fmoc deprotection. The side-chain protected peptides were detached from the resin by TFE/acetic acid/DCM [2:1:7 (v/v/v)] then subjected to cyclization using 1-hydroxy-7-azabenzotriazole (HOAT) and N,N&#x2032;-diisopropylcarbodiimide (DIC) in an anhydrous DMF/DCM mixture overnight. All protecting group were removed with cleavage cocktail of TFA/anisole/thioanisole (90:2:5 v/v/v) for 3 h. The crude products were precipitated by the addition of cold diethyl ether purified using reverse-phase HPLC using a gradient of 0-90% acetonitrile (0.1% TFA) and water (0.1% TFA) over 60 min with C-18 column. The purified peptide was lyophilized to yield a white powder (100 mg). The chemical structure of all synthesized peptides was elucidated using matrix-assisted laser desorption/ionization (MALDI) time-of-flight (TOF) mass spectrometer.</p><p id="p-0089" num="0087">MALDI-TOF (m/z) for [R<sub>4</sub>CW<sub>4</sub>C] (SEQ ID NO.: 95) [C<sub>74</sub>H<sub>98</sub>N<sub>26</sub>O<sub>10</sub>S<sub>2</sub>]: calcd, 1574.7401; found, 1575.578 [M+H<sup>+</sup>].</p><p id="p-0090" num="0088">Synthesis of cyclic peptides cyclized through a disulfide bridge. About 30 mg of the linear peptide was dissolved in a 10% DMSO-H<sub>2</sub>O solution (150 ml). The reaction mixture was stirred for 24-72 h at room temperature in an open round-bottomed flask. The reaction mixture was injected directly in reverse phase HPLC using a gradient of 0-90% acetonitrile (0.1% TFA) and water (0.1% TFA) over 60 min with C-18 column. The purified peptide was lyophilized to yield a white powder (20 mg). The chemical structure of all synthesized peptides was elucidated using matrix-assisted laser desorption/ionization (MALDI) time-of-flight (TOF) mass spectrometer.</p><p id="p-0091" num="0089">MALDI-TOF (m/z) for ([C(WR)<sub>4</sub>C]</p><p id="p-0092" num="0000"><chemistry id="CHEM-US-00003" num="00003"><img id="EMI-C00003" he="7.54mm" wi="9.91mm" file="US20230000999A1-20230105-C00003.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0093" num="0000">(SEQ ID NO.: 100) [C<sub>74</sub>H<sub>98</sub>N<sub>26</sub>O<sub>11</sub>S<sub>2</sub>]: calcd, 1590.7350; found, 1590,8999 [M]<sup>+. </sup></p><p id="p-0094" num="0090">MALDI-TOF (m/z) for [C(WR)<sub>5</sub>C]</p><p id="p-0095" num="0000"><chemistry id="CHEM-US-00004" num="00004"><img id="EMI-C00004" he="7.45mm" wi="9.91mm" file="US20230000999A1-20230105-C00004.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0096" num="0000">(SEQ ID NO.: 101) [C<sub>91</sub>H<sub>120</sub>N<sub>32</sub>O<sub>13</sub>S<sub>2</sub>]: calcd,1932.9154; found, 1932.9976 [M]<sup>+. </sup></p><p id="p-0097" num="0091">MALDI-TOF (m/z) for</p><p id="p-0098" num="0000"><chemistry id="CHEM-US-00005" num="00005"><img id="EMI-C00005" he="7.45mm" wi="9.23mm" file="US20230000999A1-20230105-C00005.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0099" num="0000">[C<sub>74</sub>H<sub>98</sub>N<sub>26</sub>O<sub>11</sub>S<sub>2</sub>]: calcd, 1590,7350; found. 1591.161 [M+H]<sup>+. </sup></p><p id="p-0100" num="0092">MALDI-TOF (m/z) for</p><p id="p-0101" num="0000"><chemistry id="CHEM-US-00006" num="00006"><img id="EMI-C00006" he="7.45mm" wi="9.23mm" file="US20230000999A1-20230105-C00006.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0102" num="0000">[C<sub>91</sub>H<sub>120</sub>N<sub>32</sub>O<sub>13</sub>S<sub>2</sub>]: calcd, 1932.9154; found, 1937.6542 [M]<sup>+. </sup></p><p id="p-0103" num="0093">MALDI-TOF (m/z) for</p><p id="p-0104" num="0000"><chemistry id="CHEM-US-00007" num="00007"><img id="EMI-C00007" he="7.45mm" wi="10.92mm" file="US20230000999A1-20230105-C00007.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0105" num="0000">[C<sub>74</sub>H<sub>96</sub>N<sub>26</sub>O<sub>10</sub>S<sub>2</sub>]: calcd, 1572.7244; found, 1573,148 [M+H]<sup>+. </sup></p><p id="p-0106" num="0094">MALDI-TOF (m/z) for R<sub>4</sub>[CW<sub>4</sub>C] [C<sub>74</sub>H<sub>98</sub>N<sub>26</sub>O<sub>11</sub>S<sub>2</sub>]: calcd, 1590,7350; found, 1590.873 [M]<sup>+. </sup></p><p id="p-0107" num="0095">MALDI-TOF (m/z) for W<sub>4</sub>[CR<sub>4</sub>C][C<sub>74</sub>H<sub>98</sub>N<sub>26</sub>O<sub>11</sub>S<sub>2</sub>]: calcd, 1590.7350; found, 1591.286 [M+H]<sup>+. </sup></p><p id="p-0108" num="0096">MALDI-TOF (m/z) for</p><p id="p-0109" num="0000"><chemistry id="CHEM-US-00008" num="00008"><img id="EMI-C00008" he="7.45mm" wi="12.45mm" file="US20230000999A1-20230105-C00008.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0110" num="0000">[C<sub>80</sub>H<sub>110</sub>N<sub>30</sub>O<sub>12</sub>S<sub>2</sub>]: calcd, 1746.8410; found, 1746.994 [M]<sup>+. </sup></p><p id="p-0111" num="0097">MALDI-TOF (m/z) for</p><p id="p-0112" num="0000"><chemistry id="CHEM-US-00009" num="00009"><img id="EMI-C00009" he="7.45mm" wi="12.45mm" file="US20230000999A1-20230105-C00009.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0113" num="0000">[C<sub>102</sub>H<sub>130</sub>N<sub>34</sub>O<sub>14</sub>S<sub>2</sub>]: calcd, 2118.9991; found, 2119.1252 [M]<sup>+. </sup></p><p id="p-0114" num="0098">MALDI-TOF (m/z) for</p><p id="p-0115" num="0000"><chemistry id="CHEM-US-00010" num="00010"><img id="EMI-C00010" he="7.45mm" wi="12.45mm" file="US20230000999A1-20230105-C00010.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0116" num="0000">[C<sub>124</sub>H<sub>151</sub>N<sub>39</sub>O<sub>15</sub>S<sub>2</sub>]: calcd, 2491.1850, found, 2491.5856 [M]<sup>+. </sup></p><p id="p-0117" num="0099">MALDI-TOF (m/z) for (W)<sub>2</sub>[KR<sub>5</sub>K](W)<sub>2</sub>[C<sub>86</sub>H<sub>124</sub>N<sub>32</sub>O<sub>11</sub>]: calcd, 1781.0127; found, 1781.61 [M]<sup>+. </sup></p><p id="p-0118" num="0100">MALDI-TOF (m/z) for (W)[KR<sub>5</sub>K](W) [C<sub>63</sub>H<sub>104</sub>N<sub>28</sub>O<sub>9</sub>]: calcd, 1408.8541; found, 1410,0432 [M+H]<sup>+. </sup></p><p id="p-0119" num="0101">As representative examples, the synthesis of representative linear and cyclic peptides is shown in <figref idref="DRAWINGS">FIGS. <b>6</b> and <b>7</b></figref>, as explained previously (Mohammed et al., Comparative molecular transporter properties acyclic peptides containing tryptophan and arginine residues formed through disulfide cyclization. <i>Molecules </i>2020, 25(11); E2581. doi: 10.3390/molecules 25112581). Parentheses ( )and brackets represent [ ] linear and cyclic peptides, respectively. Also, letters land c to represent linear and cyclic peptides. respectively. The linear peptide containing alternative tryptophan and arginine amino acids with two cysteine residues (CWRWRWRWRC) was assembled on the cysteine preloaded chlorotrityl resin using coupling and deprotecting reagents as depicted in <figref idref="DRAWINGS">FIG. <b>8</b></figref>. The linear peptide was completely cleaved in the presence of freshly prepared cleavage cocktail containing trifluoroacetic acid (TFA)/thioanisole/1,2-ethanedithiol (EDT)/anisole (90:5:3:2 v/v/v/v) to afford I(C(WR)<sub>4</sub>C). The linear peptide was subjected to the oxidation reaction using 10% DMSO-H<sub>2</sub>O solution over 24 h at room temperature to afford disulfide-linked cyclic peptide. Peptides were characterized and purified using matrix-assisted laser desorption/ionization (MALDI) mass spectroscopy and reverse-phase high-performance liquid chromatography (RP-HPLC), respectively. The analytical HPLC data showed a retention time (RT) of 9.6 and 9.8 min for the linear peptides (C(WR)4C) (SEQ ID NO.: 102) and (C(WR)5C) ((SEQ ID NO,:103), respectively, while the RT for cyclic peptides [C(WR)<sub>4</sub>C](SEQ ID NO.: 100) and [C(WR)<sub>5</sub>C](SEQ ID NO.: 101) were 10.3 and 10.5 min, respectively.</p><p id="p-0120" num="0102">Synthesis of Gold nanoparticles. In a typical synthesis, an aqueous solution of peptide and chloroauric acid were mixed in the equimolar ratio (1:1) (2 mM peptide solution and 2 mM chloroauric acid) and stirred at room temperature for 24 hours (<figref idref="DRAWINGS">FIG. <b>10</b></figref>).</p><p id="p-0121" num="0103">Synthesis of the pegylated cell-penetrating peptide (PEG-CPP). The solid-phase synthesis of the linear peptide sequence was conducted using the standard protocol mentioned before. The desired peptide sequence was assembled on rink amide resin. Orthogonal protected Cys(StBu) residues were incorporated to achieve on-resin sulfur bridge formation. N-Terminal of parent peptide was further extended by coupling 2-Fmoc aminoethoxy acetic acid as a spacer between the parent peptide and another cysteine residue Cys(Mmt), which was installed to pegylate the peptide by exploiting free side chain thiol functionality. The tent-butyl thiol groups were deprotected on resin using 3.8 mmol dithiothreitol (DTT) in 2.5 mL DMF with 0.25 mL DIEA. The reaction proceeded at 60&#xb0; C. for 20 minutes. The resin was washed thoroughly with DMF and DCM. On-resin disulfide formation reaction was conducted using N-chlorosuccinimide (NCS, 2 eq.) in DMF Methoxytrityl group was deprotected selectively by repeatedly treating the peptidyl resin with 2% TFA in DCM. The resulted free thiol functionality was used for pegylation of the peptide by reacting with preactivated PEG (mPEG-OPSS; Orthopyridyl disulfide). For on-resin pegylation reaction, 2 eq. of preactivated PEG-SH was added to the peptidyl resin in DMF. The reaction mixture was kept for shaking at room temperature for around 14 hours (<figref idref="DRAWINGS">FIG. <b>13</b></figref>). The pegylated peptide was cleaved from the resin and purified by RP-HPLC and mass was confirmed by Q-TOF-LC-MS.</p><p id="p-0122" num="0104">Synthesis of pegylated targeting peptide (PEG-TP). Synthesis of pegylated targeting peptide was conducted on wang resin as represented in the scheme (<figref idref="DRAWINGS">FIG. <b>13</b></figref>). Following the synthesis of the linear octameric peptide, on-resin lactamization was conducted through an amide bond formation between free side-chain carboxylic and amine functionality of Glu and Lys, respectively. The lactamization reaction was performed using tetrakis(tripbenylphosphine)palladium (10 eq.) and phenylsilane (3 eq.) in dry DCM. The reaction was proceeded by bubbling nitrogen and repeated twice for 15 min each. After completion of lactamization reaction, peptidyl resin was washed thoroughly with DMF and DCM. The targeting peptide was pegylated by amide bond formation between N-terminal free amine of peptide and free carboxylic group of bifunctional PEG (OPSS-PEG-COOH; Orthopyridyl disulfide PEG Carboxylic acid). The pegylated peptide was cleaved from resin and purified by RP-HPLC and mass was confirmed by Q-TOF-LC-MS.</p><p id="p-0123" num="0105">Synthesis of the final conjugate (TP-PEG-CPP). As depicted in the scheme, the final conjugate was synthesized by sulfur bridge formation between pegylated targeting peptide (PEG-TP) and cell-penetrating peptide (CPP). Purified pegylated targeting peptide (2 equiv.) having preactivated thiol was added to peptidyl resin in DMF. The reaction mixture was kept for shaking at room temperature for around 14 hours. Final conjugate was cleaved from the resin and purified by RP-HPLC and mass was confirmed by Q-TOF-LC-MS.</p><p id="p-0124" num="0106">Complex formation with modified peptides and siRNA. The peptide/siRNA complexes were formed in different N/P ratios for the variety of the in vitro studies conducted according to the previously reported procedure (Mozaffari et al., 2019). The complexes formed spontaneously based on ion/ion interaction in normal saline. For each formulation, the required amount of scrambled siRNA stock solution (10 &#x3bc;M) was added to normal saline, and then, the calculated amount of peptide stock solution (1 mg/mL) was added to the solution. The mixture was gently mixed and was incubated at room temperature for 30 minutes to ensure complete complexation. The peptide:siRNA ratios used in complex formations are reported as weight/weight ratios, as well as nitrogen/phosphate (N/P) ratios. The N/P ratios were calculated using the following formula:</p><p id="p-0125" num="0000"><br/><?in-line-formulae description="In-line Formulae" end="lead"?>NP=(#of Moles peptide&#xd7;# of nitrogens in each molecule of peptide) (#of Moles of siRNA&#xd7;# of phosphate groups in each molecule)<?in-line-formulae description="In-line Formulae" end="tail"?></p><p id="p-0126" num="0107">All siRNAs used in this project contain 21-25 base pairs in each strand. The scrambled siRNA used in this set of experiments contains 23 base pairs.</p><p id="p-0127" num="0108">Size and Surface Charges. The efficiency of siRNA carriers largely depends on the size and overall surface charge of the complex. Dynamic light scattering (DLS) was used to determine the size and &#x3b6;-potential at different N/P ratios to determine the optimal N/P ratio for a compact complex (50-200 nm) and slightly positive charge.</p><p id="p-0128" num="0109">siRNA binding affinity. To evaluate binding affinity to siRNA, a study was designed based on the quantification of free siRNA using SYBR Green II. Peptides were mixed with siRNA with a wide range of N/P ratios (0.05-40), and the amount of unbound siRNA was quantified by the fluorescent signal of SYBR Green II. The required N/P ratio for 50% binding (BC50) was calculated for each peptide.</p><p id="p-0129" num="0110">Serum Stability. In order to determine the capability of the complexes to protect the siRNA against enzymatic degradation, Inventors exposed different study groups to a diluted fetal bovine serum (FBS) solution, with &#x201c;naked&#x201d; siRNA as a positive control, and siRNA exposed to saline as a negative control according to the previously reported procedure (Mozaffari et al., 2019), and the results are summarized in <figref idref="DRAWINGS">FIG. <b>14</b></figref>. A higher concentration of FBS (25%) was used to determine the stability of siRNA in a harsher condition and a more biologically-relevant environment. After 24 hours of exposure, siRNA bands were quantified by electrophoresis. After 24 h exposure to serum, Inventors did not observe any bands for siRNA in the positive control groups, which indicated complete degradation of &#x201c;naked&#x201d; siRNA in these conditions, and validated the method. All peptides were able to protect siRNA. almost completely after 24 h incubation with the serum at 37&#xb0; C. at N/P ratios of 40. Significant protection that approached 100% with increasing the N/P ratio to 40:1.</p><p id="p-0130" num="0111">The binding affinity for [CR<sub>4</sub>W<sub>4</sub>C](SEQ ID NO.: 16) and W<sub>4</sub>[CR<sub>5</sub>C]W<sub>4</sub>(SEQ ID NO.: 52) showed that approximately 4 and 10 N/P ratios are required for 50% binding. While &#x201c;naked&#x201d; siRNA. was completely degraded in the presence of serum, both peptides were able to protect siRNA completely after 24 hours of exposure to the serum (as compared to siRNA exposed to saline as negative control) at an N/P ratio of 40 (<figref idref="DRAWINGS">FIG. <b>14</b></figref>). The toxicity of the peptides was evaluated in triple-negative breast cancer (TNBC) cells MDA-MB-231 (as a model cancer cell line) with peptide alone and siRNA complexes, and CCK assay to quantify cell viability after 48 hours.</p><p id="p-0131" num="0112">Protection of siRNA against Enzymatic Degradation. In order to study the capability of the fatty acid-conjugated linear and cyclic peptides to enhance the stability of siRNA in biological environments, samples of unprotected scrambled siRNA (positive control) and peptide/siRNA complexes at a different peptide:siRNA ratios were exposed to fetal bovine serum (FBS) solutions. After completion of complex formation for each formulation, each sample was added to a 25% v/v FBS solution in HBSS, and the mixture was incubated at 37&#xb0; C. for 24 h. A sample of unprotected siRNA in HBSS was used as a negative control, representing 100% intact siRNA. After the incubation, complexes were dissociated using a 2:3 mixture of heparin (5% solution in normal saline) and EDTA (0.5 mM), and the samples were analyzed using a 1% agarose gel (with 1 &#x3bc;g/mL ethidium bromide) at 70 V for 20 minutes. UV illumination (Gel-Doc system, Bio-Rad; Hercules, CA) was used to visualize the gel, and the intensity of the bands (representing remaining intact siRNA) was quantified by Image J software.</p><p id="p-0132" num="0113">Cylotoxicity Assays. The cytotoxicity of the peptides was evaluated in a panel of cancer and non-cancerous cell lines. Normal human breast (Hs 578Bst, ATCC&#x2122; HTR-125&#x2122;), kidney (LLCP-K1, ATCC CRL-1392), prostate (RWPE-1; ATCC&#x2122; CRL-11609&#x2122;), colon (CCD-33Co; ATCC&#x2122; CRL-1539&#x2122;), heart (H9C2. ATCC CRL 1446) or endometrial (KC02-44D hTERT, ATCC&#x2122; SC-6000&#x2122;) cell lines were exposed to a wide range of peptide/siRNA concentrations. Due to the popularity of siRNA silencing in cancer research, the toxicity of the same study groups were also evaluated in TNBC cells MDA-MB-231 (ATCC&#x2122; HTB-26&#x2122;), MDA-MB-468 (ATCC&#x2122; HTB-132), ovarian SK-OV-3 (ATCC&#x2122; HTB-77&#x2122;), colorectal ht-29 (ATCC&#x2122; HTB-38&#x2122;), and prostate LNCaP (ATCC&#x2122; CRL-174&#x2122;) cancer cell lines. Cell viability was evaluated by CCK assay after 48 hours of exposure. Neither of the peptides showed significant toxicity in the range of concentration or N/P ratio evaluated (<figref idref="DRAWINGS">FIG. <b>16</b></figref>).</p><p id="p-0133" num="0114">The human breast cancer cell line MDA-MB-231 was purchased from American Type Culture Collection (ATCC; Manassas, Va.). MDA-MB-231 was cultured in the DMEM medium. The media was supplemented with 10% (v/v) fetal bovine serum, 100 U/mL penicillin, and 100 &#x3bc;g/ml streptomycin. Cells were maintained in the normal condition of 37&#xb0; C. and 5% CO<sub>2 </sub>under a humidified atmosphere and were sub-cultured when 80-100% confluent.</p><p id="p-0134" num="0115">The &#x26;Tea of peptides on the viability of human cell lines was evaluated by exposing the MDA-MB-231 cell lines (<figref idref="DRAWINGS">FIG. <b>17</b></figref>) to different concentrations of peptide solution and exposing the cells to peptide/siRNA complexes prepared with different peptides at a various peptide:siRNA ratios according to the previously reported procedure by us (Mozaffari et al., 2019). Confluent cultures (&#x2248;800,000 cells/mL) of MDA-MB-231 cancer cell lines were seeded in 96-well plates. After 24 h, cells were exposed to different concentrations of peptide solutions or peptide/siRNA complexes. The final concentration of scrambled siRNA was 36 nM in all cytotoxicity studies performed with peptide/siRNA complexes. The cells were then incubated for 48 hours at 37&#xb0; C. with controlled CO<sub>2 </sub>and humidity. A standard 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyttetrazolium bromide (MTT) assay was performed after the incubation period to determine the cell viability, as a. percentage of untreated (NT) cells. In MDA231 cells, the peptides did not show significant cytotoxicity at a N/P ratio 40.1, both alone and incorporated in the siRNA complex.</p><p id="p-0135" num="0116">Cellular Uptake. Cellular uptake was quantified using flow cytometry and was evaluated in all the cell lines included in the cytotoxicity study. However, since this method did not confirm cytoplasmic accumulation, confocal microscopy was performed to confirm and visualize the cytoplasmic delivery. Free siRNA and Lipofectamine&#x2122; were used as negative and positive controls, respectively.</p><p id="p-0136" num="0117">Cellular internalization was studied in MDA-MB-231 using flow cytometry and confocal microscopy. The percentage of cells identified as siRNA-positive for the complexes formed with two lead peptides using an N/P ratio of 20 was comparable to the percentage of cells achieved using commercially available Lipofectamine&#x2122; 2000 (&#x2dc;63% vs. 72%; <figref idref="DRAWINGS">FIG. <b>18</b></figref>).</p><p id="p-0137" num="0118">The ability of peptides to deliver siRNA into the MDA-MB-231 cells was evaluated using FAM-labeled scrambled siRNA and analysis by flow cytometry (<figref idref="DRAWINGS">FIG. <b>19</b></figref>) according to the previously reported procedure by us (Mozaffari et al., 2019). MDA-MB-231 cells were used for these studies and were seeded in 24-well plates (&#x2248;200,000 cells per well). After the addition of the siRNA complexes to cell culture media, cells were incubated at 37&#xb0; C. and standard growth conditions for 24 hours. After the incubation period, and for flow cytometry studies, cells were washed with clear HBSS (x2), trypsinized, and fixed using 3.7% formaldehyde solution. Suspended cells were analyzed with a BD-FACSVerse (BD Biosciences; San Jose, Calif.) using the FITC channel to quantify cell-associated fluorescence. After each flow cytometry analysis, the percentage of cells with fluorescence signal and the mean fluorescence of the cell population were calculated based on the calibration of the signal gated with non-treated cells (as the negative control), so that the auto-fluorescence would be &#x2248;1% of the population.</p><p id="p-0138" num="0119">The peptides showed significant siRNA uptake, which was significantly higher at a peptide:siRNA ratio of 20:1 and 40:1 after 24 h incubation. The mean fluorescence results and positive fluorescence cells confirmed a similar pattern. The addition of PEGylated peptide (25%) in the native peptide solution enhances the uptake of siRNA.</p><p id="p-0139" num="0120">The efficiency of siRNA uptake in this cell line was also confirmed with confocal microscopy images (<figref idref="DRAWINGS">FIG. <b>22</b></figref>). The siRNA silencing efficiency were also evaluated in the same cells targeting signal transducer and activator of transcription 3 (STAT3) as a model protein. STAT3 is a well-studied protein with a central role in JAK2/STAT3 pathway and cancer cell proliferation and survival. The expression level of the targeted protein was assessed using Western Blot, which showed comparable silencing efficiency of lead peptides to Lipofectamine&#x2122; 2000 (<figref idref="DRAWINGS">FIG. <b>23</b></figref>).</p><p id="p-0140" num="0121">The siRNA silencing efficiency were also evaluated in the same cells targeting signal transducer and activator of transcription 3 (STAT3) as a model protein. STAT3 is a well-studied protein with a central role in JAK2/STAT3 pathway and cancer cell proliferation and survival. The expression level of targeted protein was assessed using Western Blot, which showed comparable silencing efficiency of lead peptides to Lipofectamine&#x2122; 2000 (<figref idref="DRAWINGS">FIG. <b>23</b></figref>).</p><p id="p-0141" num="0122">Methodology for Cell-Based Assays. Cell Lines: The human breast cancer cell line MDA-MB-231 was purchased from American Type Culture Collection (ATCC; Manassas, Va.). MDA-MB-231 was cultured in the DMEM medium. The media was supplemented with 10% (v/v) fetal bovine serum, 100 U/mL penicillin, and 100 &#x3bc;g/ml streptomycin. Cells were maintained in the normal condition of 37&#xb0; C. and 5% CO<sub>2 </sub>under a humidified atmosphere and were sub-cultured when 80-100% confluent.</p><p id="p-0142" num="0123">Toxicity of the Peptide/siRNA Complexes: The safety profile of the peptides was evaluated in two different human cancer cell lines, by exposing the cells to the peptides alone and in peptide/siRNA complexes according to the previously reported procedure (Mozaffari et al., 2019). Confluent cultures (&#x2248;800,000 cells/mL) of MDA-MB-231 cancer cell lines were seeded in 96-well plates. After 24 h, cells were exposed to different concentrations of peptide solutions or peptide/siRNA complexes. The final concentration of scrambled siRNA was 36 nM in all cytotoxicity studies performed with peptide/siRNA complexes. The cells were then incubated for 48 hours at 37&#xb0; C. with controlled CO<sub>2 </sub>and humidity. A standard 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was performed after the incubation period to determine the cell viability as a percentage of untreated (NT) cells.</p><p id="p-0143" num="0124">Internalization of siRNA into Human Cancer Cell Lines: The capability of peptides in internalizing siRNA into human cells was evaluated using FAM-labeled scrambled siRNA and flow cytometry according to the previously reported procedure (Mozaffari et al., 2019). MDA-MB-231 cells were used for these studies and were seeded in 24-well plates (&#x2248;200,000 cells per well). After the addition of the siRNA complexes to cell culture media, cells were incubated at 37&#xb0; C. and standard growth conditions for 24 hours. After the incubation period, and for flow cytometry studies, cells were washed with clear HBSS (x2), trypsinized, and fixed using 3.7% formaldehyde solution. Suspended cells were analyzed with a BD-FACSVerse (BD Biosciences; San Jose, Calif.) using the FITC channel to quantify cell-associated fluorescence. After each flow cytometry analysis, the percentage of cells with fluorescence signal and the mean fluorescence of the cell population were calculated based on the calibration of the signal gated with non-treated cells (as the negative control), so that the auto-fluorescence would be &#x2248;1% of the population.</p><p id="p-0144" num="0125">Gene Silencing. Signal Transducer and Activator of Transcription 3 (STAT3) protein was selected as a model protein to demonstrate the in vitro silencing efficiency of the designed modified peptides. STAT3 has been shown to play a major role in the proliferation and survival of different types of cancer, including breast cancer, and may even be involved in resistance against molecularly targeted drugs (Bousoik &#x201c;Do Inventors Know Jack&#x201d; About JAK? A Closer Look at JAK/STAT Signaling Pathway. <i>Front Oncol, </i>2018, 8:287). Along with Janus Kinase 2 (JAK2), STAT3 is among the major proteins involved in this inter-pathway crosstalk, and latest reports have led to the elucidation of a key role of the JAK/STAT signaling pathway in the development, proliferation, differentiation, and survival of cancer cell, and in fact, Vogelstein et at have included JAK/STAT pathway among 12 core cancer pathways (Cancer genome landscapes. <i>Science, </i>2013, 339:1546-58). The effect of STAT3 activation on Ras and PI3K/Akt pathways and the connections of JAK2 to PI3K and ERK pathways are examples of these inter-pathway cross-talks. Several peptides when used with siRNA, exhibited significant silencing of Stat3 similar to or better than lipofectamine (<figref idref="DRAWINGS">FIG. <b>24</b></figref>).</p><p id="p-0145" num="0126">Protein Quantification (Western Blot). The expression of the targeted protein was analyzed by western blot. Cell lysates were prepared according to the standard protocol using RIPA buffer. Briefly, cells exposed to siRNA complexes were collected by trypsinization after 48 h of exposure and were centrifuged at 600-800 RPM for 5 min. The supernatant was discarded, and the cell pellet was washed three times with ice-cold PBS. The pellet was resuspended in RIPA buffer (100 &#x3bc;L of buffer for 25 &#x3bc;L of cell pellet), and the cell lysates were then incubated on ice for one hour, during which the tubes were sonicated for 3 min every 10 min. The tubes were then centrifuged for 15 min at 12,000&#xd7;g (at 4&#xb0; C.). Microtubes were pre-cooled to transfer the supernatant, and total protein concentration was determined using BSA assay. Briefly, 200 &#x3bc;L of work reagent (50:1 A:B) was added to 25 &#x3bc;L of standard and unknown samples in triplicate into a 96-well plate, and the plate was mixed on a plate shaker for 30 s. The plate was then incubated at 37&#xb0; C. and 5% CO<sub>2 </sub>for 30 min. The absorbance was measured at 562 nm using SpectraMAX M5 microplate reader. Protein (25 &#x3bc;g) was loaded per well in a 10% Mini-PROTEAN&#x2122; TGX Stain-Free&#x2122; Protein gel using electrophoresis buffer (0.192. M glycine, 25 mM Tris, 0.1% SDS), and the electrophoresis was run for 60 min with 100 V. The gel was then transferred onto a Trans-Blot&#x2122; Turbo&#x2122; Mini PVDF membrane (Catalog no. 1704156). Membranes were blocked in BSA 5% for 3 h, and then incubated overnight (at 4&#xb0; C.) with the primary anti-body (1:1000 in TBS-T). The membrane was then washed with TBS-T three times (5 min each time) and was subsequently incubated with the secondary HRP-linked antibody (1:1000 in TBS-T) for 1 h, followed by the washing steps. Detection was done by ECL Detect Kit using CherniDoc imager (Bio-Rad).</p><p id="p-0146" num="0127">The peptide/plasmid complexes formed with different peptides were able to effectively transfect HEK293 cells with Green Fluorescence Protein (GFP)-expressing plasmid with no apparent toxicity (compared to commercially available Lipofectamine, which causes cell death and aggregation in the culture media (<figref idref="DRAWINGS">FIG. <b>29</b></figref>).</p><p id="p-0147" num="0128">It should be apparent to those skilled in the art that many more modifications besides those already described are possible without departing from the concepts herein. The disclosed subject matter, therefore, is not to be restricted except in the spirit of the appended claims. Moreover, in interpreting both the specification and the claims, all terms should be interpreted in the broadest possible manner consistent with the context. In particular, the terms &#x201c;comprises&#x201d; and &#x201c;including&#x201d; should be interpreted as referring to elements, components, or steps in a non-exclusive manner, indicating that the referenced elements, components, or steps may be present, or utilized, or combined with other elements, components, or steps that are not expressly referenced. Where the specification claims refer to at least one of something selected from the group consisting of A, B, C . . . , and N, the text should be interpreted as requiring only one element from the group, not A plus N, or B plus N, etc.</p><?detailed-description description="Detailed Description" end="tail"?></description><us-sequence-list-doc id="SEQLST-1"><sequence-list file="US20230000999A1-20230105-S00001.XML" carriers="internal-electronic" seq-file-type="ST.25"/></us-sequence-list-doc><us-chemistry idref="CHEM-US-00001" cdx-file="US20230000999A1-20230105-C00001.CDX" mol-file="US20230000999A1-20230105-C00001.MOL"/><us-chemistry idref="CHEM-US-00002" cdx-file="US20230000999A1-20230105-C00002.CDX" mol-file="US20230000999A1-20230105-C00002.MOL"/><us-chemistry idref="CHEM-US-00003" cdx-file="US20230000999A1-20230105-C00003.CDX" mol-file="US20230000999A1-20230105-C00003.MOL"/><us-chemistry idref="CHEM-US-00004" cdx-file="US20230000999A1-20230105-C00004.CDX" mol-file="US20230000999A1-20230105-C00004.MOL"/><us-chemistry idref="CHEM-US-00005" cdx-file="US20230000999A1-20230105-C00005.CDX" mol-file="US20230000999A1-20230105-C00005.MOL"/><us-chemistry idref="CHEM-US-00006" cdx-file="US20230000999A1-20230105-C00006.CDX" mol-file="US20230000999A1-20230105-C00006.MOL"/><us-chemistry idref="CHEM-US-00007" cdx-file="US20230000999A1-20230105-C00007.CDX" mol-file="US20230000999A1-20230105-C00007.MOL"/><us-chemistry idref="CHEM-US-00008" cdx-file="US20230000999A1-20230105-C00008.CDX" mol-file="US20230000999A1-20230105-C00008.MOL"/><us-chemistry idref="CHEM-US-00009" cdx-file="US20230000999A1-20230105-C00009.CDX" mol-file="US20230000999A1-20230105-C00009.MOL"/><us-chemistry idref="CHEM-US-00010" cdx-file="US20230000999A1-20230105-C00010.CDX" mol-file="US20230000999A1-20230105-C00010.MOL"/><us-claim-statement>What is claimed is:</us-claim-statement><claims id="claims"><claim id="CLM-00001" num="00001"><claim-text><b>1</b>. A composition for transferring a nucleic acid into a. living cell, comprising a cyclic peptide comprising a plurality of a positively charged amino acids X and a plurality of a hydrophobic amino acids Y, wherein positively charged amino acids X and hydrophobic amino acids Y are coupled to one another in an alternating fashion between two cysteine residues with a disulfide bridge or N- to C-terminal amide bond.</claim-text></claim><claim id="CLM-00002" num="00002"><claim-text><b>2</b>. A composition for transferring a nucleic acid into a living cell, comprising a cyclic peptide comprising a plurality of a positively charged amino acids X coupled to one another in a first segment and a plurality of a hydrophobic amino acids Y coupled to one another in a second segment, wherein the first segment and the second segment are coupled to one another between two cysteine residues with a disulfide bridge or N- to C-terminal amide bond.</claim-text></claim><claim id="CLM-00003" num="00003"><claim-text><b>3</b>. A composition for transferring nucleic acid into a living cell, comprising a peptide selected from the group consisting of a linear peptide (Y)<sub>n</sub>CX<sub>n</sub>C(Y)<sub>n </sub>or (X)<sub>n</sub>CY<sub>n</sub>C(X)<sub>n</sub>, a hybrid cyclic-linear peptide (Y)<sub>n</sub>[CX<sub>n</sub>C](Y)<sub>n</sub>, a hybrid cyclic-linear peptide (X)<sub>n</sub>[CY<sub>n</sub>C](X)<sub>n</sub>, a hybrid cyclic-linear peptide (Y)<sub>n</sub>[KX<sub>n</sub>K](Y)<sub>n</sub>, a hybrid cyclic-linear peptide (X)<sub>n</sub>[KY<sub>n</sub>K](X)<sub>n</sub>, a linear peptide (X)<sub>n</sub>(KY<sub>n</sub>K)(X)<sub>n</sub>, and a linear peptide (X)<sub>n</sub>(Y<sub>n</sub>)(X), wherein Y is a hydrophobic amino acid, X is a positively-charged amino acid, each n is independently from 1 to 10.</claim-text></claim><claim id="CLM-00004" num="00004"><claim-text><b>4</b>. A composition for transferring nucleic acid into a living cell, comprising a linear or cyclic peptide comprising a plurality of positively charged amino acids X and a plurality of hydrophobic amino acids Y separated from one another by one or more &#x3b2;-alanines.</claim-text></claim><claim id="CLM-00005" num="00005"><claim-text><b>5</b>. The composition of any one of <claim-ref idref="CLM-00001">claims 1</claim-ref>-<claim-ref idref="CLM-00004">4</claim-ref>, wherein the peptide is a linear peptide.</claim-text></claim><claim id="CLM-00006" num="00006"><claim-text><b>6</b>. The composition of any one of <claim-ref idref="CLM-00001">claims 1</claim-ref>-<claim-ref idref="CLM-00004">4</claim-ref>, wherein the peptide is a cyclic peptide having a cyclic structure, wherein the cyclic structure includes a disulfide bridge, a peptide bond generated between N-terminal and C-terminal amino acids of a linear peptide precursor, or both.</claim-text></claim><claim id="CLM-00007" num="00007"><claim-text><b>7</b>. The composition of any one of <claim-ref idref="CLM-00001">claims 1</claim-ref>-<claim-ref idref="CLM-00004">4</claim-ref>, wherein the peptide is a hybrid peptide comprising a cyclic portion having a cyclic structure and a linear portion.</claim-text></claim><claim id="CLM-00008" num="00008"><claim-text><b>8</b>. The composition of any one of <claim-ref idref="CLM-00001">claims 1</claim-ref>-<claim-ref idref="CLM-00007">7</claim-ref>, wherein the peptide further comprises a plurality of cysteine residues.</claim-text></claim><claim id="CLM-00009" num="00009"><claim-text><b>9</b>. The composition of <claim-ref idref="CLM-00008">claim 8</claim-ref>. wherein the peptide is the cyclic peptide, comprising a disulfide bond between two of the plurality of cysteine residues, wherein the disulfide bond forms part of the cyclic structure.</claim-text></claim><claim id="CLM-00010" num="00010"><claim-text><b>10</b>. The composition of <claim-ref idref="CLM-00008">claim 8</claim-ref>, wherein the peptide is the hybrid peptide, comprising a disulfide bond between two of the plurality of cysteine residues, wherein the disulfide bond forms part of the cyclic structure.</claim-text></claim><claim id="CLM-00011" num="00011"><claim-text><b>11</b>. The composition of any one of <claim-ref idref="CLM-00001">claims 1</claim-ref>-<claim-ref idref="CLM-00010">10</claim-ref>, wherein the charged amino acid X is selected from the group consisting of 1-arginine, 1-lysine, 1-histidine, d-histidine, d-arginine, d-lysine, ornithine, a modified histidine residues with a hydrocarbon side chain, C3-Arginine, C4-Arginine, diaminopropionic acid (Dap), diaminobutyric acid (Dab), an amino acid comprising a free side-chain amino or guanidine group, a modified arginine, and a modified lysine.</claim-text></claim><claim id="CLM-00012" num="00012"><claim-text><b>12</b>. The composition of any one of <claim-ref idref="CLM-00001">claims 1</claim-ref>-<claim-ref idref="CLM-00011">11</claim-ref>, wherein the hydrophobic amino acid Y is selected from the group consisting of 1-tryptophan, d-tryptophan, 1-phenylalanine, d-phenylalanine, 1-isoleucine, d-isoleucine, p-phenyl-1-phenylalanine (Bip), 3,3-diphenyl-1-alanine (Dip), 3(2-naphthyl)-1-alanine (NaI), 6-amino-2-naphthoic acid, 3-amino-2-naphthoic acid, 1,2,3,4-tetrahydronorharmane-3-carboxylic acid, 1,2,3,4-tetrahydro-3-isoquinolinecarboxylic acid (Tic-OH), 1,2,3,4-tetrahydro-3-isoquinolinecarboxylic acid, a modified d- or 1-tryptophan residue, an N-alkyl tryptophan, an N-aryl tryptophan, a substituted d- or 1-tryptophan residue, 5-hydroxy-L-tryptophan, 5-methoxy-L-tryptophan, 6-chloro-L-tryptophan, a fatty amino acid having a formula NH<sub>2</sub>-(CH<sub>2</sub>)<sub>x</sub>-COOH wherein x=1-20, and an N-heteroaromatic amino acid.</claim-text></claim><claim id="CLM-00013" num="00013"><claim-text><b>13</b>. The composition of any one of <claim-ref idref="CLM-00001">claims 1</claim-ref>-<claim-ref idref="CLM-00012">12</claim-ref>, wherein the peptide comprises a non-peptide bond linking adjacent amino acids.</claim-text></claim><claim id="CLM-00014" num="00014"><claim-text><b>14</b>. The composition of <claim-ref idref="CLM-00013">claim 13</claim-ref>, wherein the non-peptide bond is selected from the group consisting of a thioamide bond, an N-methyl bond, and a CH<sub>2</sub>-NH bond.</claim-text></claim><claim id="CLM-00015" num="00015"><claim-text><b>15</b>. The composition of any one of <claim-ref idref="CLM-00001">claims 1</claim-ref>-<claim-ref idref="CLM-00014">14</claim-ref>. wherein the peptide comprises a modification to a side chain of a charged amino acid X or a hydrophobic amino acid Y.</claim-text></claim><claim id="CLM-00016" num="00016"><claim-text><b>16</b>. The composition of <claim-ref idref="CLM-00015">claim 15</claim-ref>, wherein the modification is PEGylation.</claim-text></claim><claim id="CLM-00017" num="00017"><claim-text><b>17</b>. A composition for the delivery of a nucleic acid into a living cell, comprising:<claim-text>a peptide of any one of <claim-ref idref="CLM-00001">claims 1</claim-ref>-<claim-ref idref="CLM-00016">16</claim-ref>; and</claim-text><claim-text>a nanoparticle.</claim-text></claim-text></claim><claim id="CLM-00018" num="00018"><claim-text><b>18</b>. The composition of <claim-ref idref="CLM-00017">claim 17</claim-ref>, wherein the nanoparticle comprises gold or silver.</claim-text></claim><claim id="CLM-00019" num="00019"><claim-text><b>19</b>. The composition of <claim-ref idref="CLM-00017">claim 17</claim-ref> or <claim-ref idref="CLM-00018">18</claim-ref>, wherein the nanoparticles is a peptide-capped nanoparticle.</claim-text></claim><claim id="CLM-00020" num="00020"><claim-text><b>20</b>. The composition of any one of <claim-ref idref="CLM-00017">claims 17</claim-ref>-<claim-ref idref="CLM-00019">19</claim-ref>, further comprising the nucleic acid.</claim-text></claim><claim id="CLM-00021" num="00021"><claim-text><b>21</b>. The composition of <claim-ref idref="CLM-00020">claim 20</claim-ref>, wherein the nucleic acid is an RNA.</claim-text></claim><claim id="CLM-00022" num="00022"><claim-text><b>22</b>. The composition of <claim-ref idref="CLM-00021">claim 21</claim-ref>, wherein the RNA is an siRNA.</claim-text></claim><claim id="CLM-00023" num="00023"><claim-text><b>23</b>. The composition of <claim-ref idref="CLM-00020">claim 20</claim-ref>, wherein the nucleic acid is an DNA.</claim-text></claim><claim id="CLM-00024" num="00024"><claim-text><b>24</b>. The composition of <claim-ref idref="CLM-00020">claim 20</claim-ref>, wherein the nucleic acid is a part of CRISPR.</claim-text></claim><claim id="CLM-00025" num="00025"><claim-text><b>25</b>. The composition of any one of <claim-ref idref="CLM-00017">claims 17</claim-ref>-<claim-ref idref="CLM-00020">20</claim-ref>, wherein the composition is formulated for topical, oral, injection, or nasal administration.</claim-text></claim><claim id="CLM-00026" num="00026"><claim-text><b>26</b>. A composition for the delivery of nucleic acid into a living cell, comprising:<claim-text>a peptide of any one of <claim-ref idref="CLM-00001">claims 1</claim-ref>-<claim-ref idref="CLM-00016">16</claim-ref>; and the nucleic acid.</claim-text></claim-text></claim><claim id="CLM-00027" num="00027"><claim-text><b>27</b>. The composition of <claim-ref idref="CLM-00020">claim 20</claim-ref>, wherein the composition is formulated for topical, oral, injection, or nasal administration.</claim-text></claim><claim id="CLM-00028" num="00028"><claim-text><b>28</b>. A method of delivering a nucleic acid into a living cell, comprising:<claim-text>contacting a peptide of any one of <claim-ref idref="CLM-00001">claims 1</claim-ref>-<claim-ref idref="CLM-00016">16</claim-ref> with the nucleic acid to form a peptide:nucleic acid complex; and</claim-text><claim-text>contacting the cell with the peptide:nucleic acid complex.</claim-text></claim-text></claim><claim id="CLM-00029" num="00029"><claim-text><b>29</b>. The method of <claim-ref idref="CLM-00028">claim 28</claim-ref>, further comprising a step of isolating the peptide:nucleic acid complex prior to contacting the cell.</claim-text></claim><claim id="CLM-00030" num="00030"><claim-text><b>30</b>. The method of <claim-ref idref="CLM-00028">claim 28</claim-ref> or <claim-ref idref="CLM-00029">29</claim-ref>, wherein the peptide:nucleic acid complex further comprises a nanoparticle.</claim-text></claim><claim id="CLM-00031" num="00031"><claim-text><b>31</b>. The method of <claim-ref idref="CLM-00030">claim 30</claim-ref>, wherein the nanoparticle comprises gold or silver.</claim-text></claim><claim id="CLM-00032" num="00032"><claim-text><b>32</b>. The method of any one of <claim-ref idref="CLM-00028">claims 28</claim-ref>-<claim-ref idref="CLM-00031">31</claim-ref>, wherein the cell is selected from the group consisting of a bacterial cell, a plant cell, an animal cell, and a fungal cell.</claim-text></claim><claim id="CLM-00033" num="00033"><claim-text><b>33</b>. A method of treating a disease state in an individual, comprising:<claim-text>contacting a peptide of any one of <claim-ref idref="CLM-00001">claims 1</claim-ref>-<claim-ref idref="CLM-00016">16</claim-ref> with a nucleic acid to form a peptide:nucleic acid complex; and</claim-text><claim-text>contacting a cell obtained from the individual with the peptide:nucleic acid complex.</claim-text></claim-text></claim><claim id="CLM-00034" num="00034"><claim-text><b>34</b>. The method of <claim-ref idref="CLM-00033">claim 33</claim-ref>, further comprising a step of isolating the peptide: nucleic acid complex prior to contacting the cell.</claim-text></claim><claim id="CLM-00035" num="00035"><claim-text><b>35</b>. The method of <claim-ref idref="CLM-00033">claim 33</claim-ref> or <claim-ref idref="CLM-00034">34</claim-ref>, wherein the peptide:nucleic acid complex further comprises a nanoparticle.</claim-text></claim><claim id="CLM-00036" num="00036"><claim-text><b>36</b>. The method of <claim-ref idref="CLM-00035">claim 35</claim-ref>, wherein the nanoparticle comprises gold or silver.</claim-text></claim><claim id="CLM-00037" num="00037"><claim-text><b>37</b>. The method of any one of <claim-ref idref="CLM-00033">claims 33</claim-ref>-<claim-ref idref="CLM-00036">36</claim-ref>, wherein the disease state is selected from the group consisting of cancer, a central nervous system disorder, an autoimmune disease, a genetic disease, a proliferative disease, a hematological disease, an inflammatory disease, a gastrointestinal disease, a liver disease, a lung disease, a kidney disease, a spleen disease, a familial amyloid neuropathy, pain, a metabolic disorder, a psychiatric disorder, a bacterial infection, a viral infection, and a fungal infection.</claim-text></claim><claim id="CLM-00038" num="00038"><claim-text><b>38</b>. The method of one of <claim-ref idref="CLM-00033">claims 33</claim-ref>-<claim-ref idref="CLM-00037">37</claim-ref>, wherein the peptide:nucleic acid complex is formulated as a pharmaceutical, wherein the pharmaceutical is suitable for at least one of topical, oral, injection, nasal, vaginal, and rectal administration.</claim-text></claim><claim id="CLM-00039" num="00039"><claim-text><b>39</b>. The method of one of <claim-ref idref="CLM-00033">claims 33</claim-ref>-<claim-ref idref="CLM-00038">38</claim-ref> wherein treating comprises at least one of prophylaxis and treatment of active disease.</claim-text></claim><claim id="CLM-00040" num="00040"><claim-text><b>40</b>. A cosmetic preparation comprising:<claim-text>a peptide of any one of <claim-ref idref="CLM-00001">claims 1</claim-ref>-<claim-ref idref="CLM-00016">16</claim-ref>; and</claim-text><claim-text>a cosmetically acceptable vehicle.</claim-text></claim-text></claim><claim id="CLM-00041" num="00041"><claim-text><b>41</b>. The cosmetic preparation of <claim-ref idref="CLM-00040">claim 40</claim-ref>, further comprising a nucleic acid.</claim-text></claim><claim id="CLM-00042" num="00042"><claim-text><b>42</b>. The cosmetic preparation of <claim-ref idref="CLM-00041">claim 41</claim-ref>, wherein the nucleic acid is an RNA.</claim-text></claim><claim id="CLM-00043" num="00043"><claim-text><b>43</b>. The cosmetic preparation of <claim-ref idref="CLM-00042">claim 42</claim-ref>, wherein the RNA is an siRNA.</claim-text></claim><claim id="CLM-00044" num="00044"><claim-text><b>44</b>. The cosmetic preparation of <claim-ref idref="CLM-00041">claim 41</claim-ref>, further comprising a DNA.</claim-text></claim><claim id="CLM-00045" num="00045"><claim-text><b>45</b>. The cosmetic preparation of any one of <claim-ref idref="CLM-00040">claims 40</claim-ref>-<claim-ref idref="CLM-00044">44</claim-ref> further comprising a nanoparticle.</claim-text></claim><claim id="CLM-00046" num="00046"><claim-text><b>46</b>. The cosmetic preparation of <claim-ref idref="CLM-00045">claim 45</claim-ref>, wherein the nanoparticle comprises gold or silver.</claim-text></claim><claim id="CLM-00047" num="00047"><claim-text><b>47</b>. The cosmetic preparation of any one of <claim-ref idref="CLM-00040">claims 40</claim-ref>-<claim-ref idref="CLM-00046">46</claim-ref> wherein the cosmetic preparation is formulated as a micellar suspension, a lotion, a cream, a masque. an ointment, a gel, or a shampoo.</claim-text></claim><claim id="CLM-00048" num="00048"><claim-text><b>48</b>. Use of a composition of any one of <claim-ref idref="CLM-00001">claims 1</claim-ref>-<claim-ref idref="CLM-00016">16</claim-ref> in a food industry.</claim-text></claim><claim id="CLM-00049" num="00049"><claim-text><b>49</b>. The use of <claim-ref idref="CLM-00048">claim 48</claim-ref>, wherein the food industry is agriculture,</claim-text></claim><claim id="CLM-00050" num="00050"><claim-text><b>50</b>. The use of <claim-ref idref="CLM-00049">claim 49</claim-ref>, wherein the use is as a pesticide or herbicide.</claim-text></claim><claim id="CLM-00051" num="00051"><claim-text><b>51</b>. The use of <claim-ref idref="CLM-00048">claim 48</claim-ref>-<claim-ref idref="CLM-00050">50</claim-ref>, wherein the composition further comprises a nanoparticle.</claim-text></claim><claim id="CLM-00052" num="00052"><claim-text><b>52</b>. The use of <claim-ref idref="CLM-00051">claim 51</claim-ref>, wherein the nanoparticle comprises gold or silver.</claim-text></claim><claim id="CLM-00053" num="00053"><claim-text><b>53</b>. A composition for transferring nucleic acid into a living cell, comprising a linear peptide comprising a plurality of hydrophobic residues coupled to two chains of hydrophilic residues through two cysteine residues.</claim-text></claim><claim id="CLM-00054" num="00054"><claim-text><b>54</b>. A composition for transferring nucleic acid into a living cell, comprising a linear peptides comprising a plurality of hydrophilic residues coupled to two chains of hydrophobic residues through two cysteine residues.</claim-text></claim><claim id="CLM-00055" num="00055"><claim-text><b>55</b>. A composition for transferring nucleic acid into a living cell, comprising a cyclic peptide comprising a plurality of hydrophobic residues coupled to two chains of hydrophilic residues through two cysteine residues.</claim-text></claim><claim id="CLM-00056" num="00056"><claim-text><b>56</b>. A composition for transferring nucleic acid into a living cell, comprising a cyclic peptide comprising a plurality hydrophilic residues coupled to two chains of hydrophobic residues through two cysteine residues.</claim-text></claim><claim id="CLM-00057" num="00057"><claim-text><b>57</b>. A composition for transferring nucleic acid into a living cell, comprising a linear peptide comprising hydrophobic residues coupled to two chains of hydrophilic residues through two lysine residues.</claim-text></claim><claim id="CLM-00058" num="00058"><claim-text><b>58</b>. A composition for transferring nucleic acid into a living cell, comprising a linear peptide containing hydrophilic residues coupled to two chains of hydrophobic residues through two lysine residues.</claim-text></claim><claim id="CLM-00059" num="00059"><claim-text><b>59</b>. A composition for transferring nucleic acid into a living cell, comprising a cyclic peptide comprising a plurality of hydrophobic residues attached to two chains of hydrophilic residues through two lysine residues.</claim-text></claim><claim id="CLM-00060" num="00060"><claim-text><b>60</b>. A composition for transferring nucleic acid into a living cell, comprising a cyclic peptide comprising a plurality of hydrophilic residues coupled to two chains of hydrophobic residues through two lysine residues.</claim-text></claim><claim id="CLM-00061" num="00061"><claim-text><b>61</b>. The composition of any one of <claim-ref idref="CLM-00001">claims 1</claim-ref>-<claim-ref idref="CLM-00004">4</claim-ref> for the delivery of a nucleic acid into a living cell.</claim-text></claim><claim id="CLM-00062" num="00062"><claim-text><b>62</b>. The composition of any one of <claim-ref idref="CLM-00001">claims 1</claim-ref>-<claim-ref idref="CLM-00004">4</claim-ref> for transferring one or more siRNA into a living cell.</claim-text></claim><claim id="CLM-00063" num="00063"><claim-text><b>63</b>. The composition of any one of <claim-ref idref="CLM-00001">claims 1</claim-ref>-<claim-ref idref="CLM-00004">4</claim-ref> for transferring one or more DNA into a living cell.</claim-text></claim><claim id="CLM-00064" num="00064"><claim-text><b>64</b>. The composition of any one of <claim-ref idref="CLM-00001">claims 1</claim-ref>-<claim-ref idref="CLM-00004">4</claim-ref> for transferring one or more plasmid into a living cell.</claim-text></claim><claim id="CLM-00065" num="00065"><claim-text><b>65</b>. The composition of any one of <claim-ref idref="CLM-00001">claims 1</claim-ref>-<claim-ref idref="CLM-00004">4</claim-ref> for transferring one or more CRISPR into a living cell.</claim-text></claim><claim id="CLM-00066" num="00066"><claim-text><b>66</b>. The composition of any one of <claim-ref idref="CLM-00001">claims 1</claim-ref>-<claim-ref idref="CLM-00004">4</claim-ref> for transferring one or more hairpin RNA into a living cell.</claim-text></claim><claim id="CLM-00067" num="00067"><claim-text><b>67</b>. The composition of any one of <claim-ref idref="CLM-00001">claims 1</claim-ref>-<claim-ref idref="CLM-00004">4</claim-ref> for transferring one or more micro RNA into a living cell.</claim-text></claim><claim id="CLM-00068" num="00068"><claim-text><b>68</b>. The composition of any one of <claim-ref idref="CLM-00001">claims 1</claim-ref>-<claim-ref idref="CLM-00004">4</claim-ref> for transferring one or more oligonucleotides into a living cell.</claim-text></claim><claim id="CLM-00069" num="00069"><claim-text><b>69</b>. The composition of any one of <claim-ref idref="CLM-00001">claims 1</claim-ref>-<claim-ref idref="CLM-00004">4</claim-ref> for transferring any negatively charged molecules, such as phosphopeptides and phosphoproteins.</claim-text></claim><claim id="CLM-00070" num="00070"><claim-text><b>70</b>. The composition of any one of <claim-ref idref="CLM-00001">claims 1</claim-ref>-<claim-ref idref="CLM-00004">4</claim-ref> that is used as transfecting agents.</claim-text></claim><claim id="CLM-00071" num="00071"><claim-text><b>71</b>. The method of any one of <claim-ref idref="CLM-00033">claims 33</claim-ref>-<claim-ref idref="CLM-00036">36</claim-ref> for treatment or mitigating viral infections.</claim-text></claim><claim id="CLM-00072" num="00072"><claim-text><b>72</b>. The method of any one of <claim-ref idref="CLM-00033">claims 33</claim-ref>-<claim-ref idref="CLM-00036">36</claim-ref>, wherein the peptide-nucleic acid complex is used as a vaccine for prevention of disease.</claim-text></claim><claim id="CLM-00073" num="00073"><claim-text><b>73</b>. The method of <claim-ref idref="CLM-00033">claim 33</claim-ref>, wherein treating comprises at least one of prophylaxis and treatment of active disease.</claim-text></claim><claim id="CLM-00073-1" num="00073-1"><claim-text><b>73</b>. The composition of any one of <claim-ref idref="CLM-00001">claims 1</claim-ref>-<claim-ref idref="CLM-00004">4</claim-ref>, wherein the peptide is pegylated.</claim-text></claim><claim id="CLM-00074" num="00074"><claim-text><b>74</b>. The composition of any one of <claim-ref idref="CLM-00001">claims 1</claim-ref>-<claim-ref idref="CLM-00004">4</claim-ref>, wherein the peptide is attached to a targeting moiety directly or through conjugation with PEG.</claim-text></claim></claims></us-patent-application>